Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Abacavir or its saltsPDL I DEC / 13
AbataceptPDL I DEC / 13
AbciximabPDL I DEC / 13
Abiraterone or its derivativesPDL

including but not limited to abiraterone acetate

I DEC / 13
Acamprosate or its saltsPDL I DEC / 13
Acarbose or its derivativesPDL I DEC / 13
Acebutolol or its saltsPDL I DEC / 13
Acepromazine or its saltsPDL

for human use

I DEC / 13
AcetaminophenPDL

when recommended for administration by intravenous injection

I DEC / 13
Acetaminophen in sustained release formulations

up to and including 650 mg per unit, in package sizes containing no more than 50 units

U JAN / 03
Acetaminophen in sustained release formulations.

in strengths of greater than 650 mg per unit or in package sizes of more than 50 units

III JAN / 03
Acetaminophen. in immediate release tablets, capsules, suppositories or liquid U SEP / 99
AcetanilidePDL

for human use

I DEC / 13
Acetarsol II SEP / 98
AcetazolamidePDL I DEC / 13
AcetohexamidePDL I DEC / 13
AcetorphineN I JUN / 02
Acetyl-a-methylfentanylN I JUN / 02
AcetylcarbromalPDL I DEC / 13
Acetylcholine ChloridePDL I DEC / 13
Acetylcysteine II SEP / 98
AcetyldihydrocodeineN I JUN / 02
AcetylmethadolN I JUN / 02
Acetylsalicylic acid and its salts oral preparations containing 80 mg or less per dosage unit and intended for pediatric use or rectal preparations containing 150 mg or less per dosage unit, in package sizes containing no more than 1.92 g of acetylsalicylic acid. II FEB / 02
Acetylsalicylic acid and its salts. in products for oral use in strengths of 325mg and 500mg per dosage unit U OCT / 00
Acetylsalicylic acid and its salts.. in products intended for oral adult use in strengths of 81 mg per dosage unit and 650 mg or greater per dosage unit, and in rectal preparations containing more than 150 mg per dosage unit III OCT / 00
Acitretin or its salts or derivativesPDL I DEC / 13
Aclidinium or its saltsPDL I DEC / 13
Aconiazide or its saltsPDL I DEC / 13
Acyclovir or its saltsPDL I DEC / 13
AdalimumabPDL I DEC / 13
Adapalene or its salts or derivativesPDL I DEC / 13
Adefovir or its salts or derivativesPDL

including but not limited to adefovir dipivoxil

I DEC / 13
Adenosine or its saltsPDL

when sold or recommended for administration by intravenous injection

I DEC / 13
Adiphene and its salts for parenteral use II SEP / 98
Adrenocortical hormones or their salts or derivativesPDL

for human use including but not limited to: Betamethasone valerate, betamethasone sodium, betamethasone phosphate, betamethasone dipropionate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasone sodium, dexamethasone phosphate, dexamethasone acetate, difluprednate, fludrocortisone acetate, flunisolide, fluticasone propionate, fluticasone furoate, hydrocortisone acetate, hydrocortisone aceponate, hydrocortisone sodium, methylprednisolone acetate, methylprednisolone, methylprednisolone succinate, methylprednisolone sodium, mometasone furoate, prednisolone acetate, prednisolone sodium, prednisolone phosphate, prednisone, triamcinolone acetonide, triamcinolone hexacetonide except: (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other nonprescription medicinal ingredient that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (c) clobetasone butyrate when sold in a concentration of 0.05% in cream preparations for topical use on the skin; or (d) triamcinolone acetonide in a nasal spray that delivers 55 microgram (mcg)/spray for those 12 years of age and older; or, (e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older; or (f) fluticasone propionate for the treatment of allergic rhinitis in a nasal spray that delivers 50 microgram/spray for those 18 years of age and older.

I AUG / 16
Afatinib or its saltsPDL I DEC / 13
AfliberceptPDL I DEC / 13
AfoxolanerPDL I AUG / 14
Agalsidase AlfaPDL I APR / 07
Agalsidase BetaPDL I DEC / 14
AlbiglutidePDL I AUG / 15
AldesleukinPDL I DEC / 13
Alectinib or its saltsPDL I NOV / 16
AlefaceptPDL I DEC / 13
AlemtuzumabPDL I DEC / 13
Alendronic acid or its saltsPDL I DEC / 13
AlfacalcidolPDL I DEC / 13
AlfentanilN I JUN / 02
Alfuzosin or its saltsPDL I DEC / 13
Alglucosidase alfaPDL I DEC / 13
AlirocumabPDL I AUG / 16
Aliskiren or its saltsPDL I DEC / 13
Alitretinoin or its salts or derivativesPDL I DEC / 13
Alkyl nitritesPDL I DEC / 13
Allergy serums and extracts I SEP / 99
Allethrins II SEP / 98
AllobarbitalC2 I JUN / 02
AllopurinolPDL I DEC / 13
AllylisopropylacetylureaPDL I DEC / 13
AllylprodineN I JUN / 02
Almotriptan or its saltsPDL I DEC / 13
Aloe vera latex, its extracts and derivatives[except aloin] dosage forms for systemic use containing more than 300 mg per dosage unit III SEP / 98
Alogliptin or its salts or its derivativesPDL I DEC / 13
Aloin U
Alpha-chloralosePDL I DEC / 13
Alpha-hydroxy acidsPDL

including but not limited to citric acid, glycolic acid, lactic acid, malic acid, mandelic acid, ammonium glycolate, glycolic acid + ammonium glycolate, alpha-hydroxyethanoic acid + ammonium alpha-hydroxyethanoate, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, triple fruit acid, tri-alpha hydroxy fruit acids, alpha hydroxy and botanical complex, l-alpha hydroxy acid, glycomer in cross-linked fatty acids alpha nutrium, when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations of greater than 30% and/or with a pH lower than 3.0, except when sold to be applied to warts, corns or calluses

I DEC / 14
AlphacetylmethadolN I JUN / 02
Alphadolone or its saltsPDL I DEC / 13
AlphameprodineN I JUN / 02
AlphamethadolN I JUN / 02
AlphaprodineN I JUN / 02
AlphaxalonePDL

including but not limited to alfaxalone, alphaxolone

I DEC / 13
AlphenalC2 I JUN / 02
AlprazolamTS I SEP / 98
Alteplase or its salts or derivativesPDL

including but not limited to tenecteplase

I DEC / 13
AltrenogestPDL I DEC / 13
AltretaminePDL I DEC / 13
Aluminum oxide III SEP / 98
Alverine and its salts for parenteral use I SEP / 98
Amantadine or its saltsPDL I DEC / 13
Ambenonium ChloridePDL I DEC / 13
AmbrisentanPDL I DEC / 13
Amifostine or its saltsPDL I DEC / 13
Amikacin or its salts or derivativesPDL

PDL, including but not limited to amikacin sulfate

I DEC / 13
Amiloride or its saltsPDL I DEC / 13
Amino Acid solutions for parenteral use I SEP / 99
Amino-pteroyl aspartic acid or its saltsPDL I DEC / 13
Aminocaproic acidPDL I DEC / 13
AminoglutethimidePDL I DEC / 13
Aminolevulinic acid or its salts or derivativesPDL I DEC / 13
AminophyllinePDL I DEC / 13
Aminopromazine [proquamezine] and its salts I SEP / 98
Aminopterin or its salts or derivativesPDL I DEC / 13
Aminopyrine or its derivativesPDL

for human use

I DEC / 13
Aminorex and any salt thereofC4 I JAN / 03
Aminosalicylic Acid or its saltsPDL I DEC / 13
Aminosalicylic acidPDL

including but not limited to mesalazine

I DEC / 13
Amiodarone or its salts or derivativesPDL

including but not limited to dronedarone

I DEC / 13
AmitrazPDL I DEC / 13
Amitriptyline or its saltsPDL I DEC / 13
Amlexanox or its salts or derivativesPDL I DEC / 13
Amlodipine or its saltsPDL I DEC / 13
Ammonium bromidePDL I DEC / 13
Ammonium hydroxide U
AmobarbitalC2 I JUN / 02
AmoxapinePDL I DEC / 13
AmphetamineC1 I JUN / 02
Amphotericin B or its salts or derivativesPDL I DEC / 13
Amprenavir or its salts or derivatives

including but not limited to fosamprenavir

I DEC / 13
Amprolium or its saltsPDL

for human use

I DEC / 13
Amrinone or its saltsPDL I DEC / 13
Amsacrine or its saltsPDL I DEC / 13
Amylocaine and its salts in preparations for topical use on mucous membranes except lozenges III SEP / 98
Amylocaine and its salts for ophthalmic or parenteral use II SEP / 98
Anagrelide or its saltsPDL I DEC / 13
Anakinra or its salts or derivativesPDL I DEC / 13
AnastrozolePDL I DEC / 13
AncestimPDL I DEC / 13
AndroisoxazoleC3 I JUN / 02
AndrostanoloneC3 I JUN / 02
AndrostenediolC3 I JUN / 02
Anetholtrithione III SEP / 98
AnidulafunginPDL I DEC / 13
AnileridineN I JUN / 02
Anisotropine and its salts II SEP / 98
Antazoline and its salts III SEP / 98
Anthralin II SEP / 98
Anti-thymocyte globulinPDL I DEC / 13
Antihemophilic factor, human II SEP / 98
AntipyrinePDL

for human use, except preparations for topical use

I DEC / 13
Antipyrine.

except otic preparations

II SEP / 98
Antipyrine..

for otic use

III SEP / 98
Apixaban or its derivativesPDL I DEC / 13
Apomorphine or its saltsPDL I FEB / 17
Apraclonidine or its saltsPDL I DEC / 13
Apramycin or its saltsPDL

for human use

I DEC / 13
ApremilastPDL I DEC / 14
Aprepitant or its derivativesPDL

including but not limited to fosaprepitant

I DEC / 13
AprobarbitalC2 I JUN / 02
AprotininPDL I DEC / 13
Argatroban or its salts or derivativesPDL I DEC / 13
Arginine and its salts II SEP / 98
Aripiprazole or its saltsPDL I DEC / 13
Arsenic trioxidePDL I DEC / 13
Artemisia, its preparations, extracts and compounds except in trace amounts in homeopathic preparations II SEP / 98
Asenapine or its salts or derivativesPDL

including but not limited to asenapine maleate

I DEC / 13
Asfotase alfaPDL I OCT / 15
AsparaginasePDL

when sold for administration by injection

I DEC / 13
Astemizole or its saltsPDL I DEC / 13
AsunaprevirPDL I AUG / 16
Atazanavir or its saltsPDL I DEC / 13
Atenolol or its saltsPDL I DEC / 13
AtezolizumabPDL I MAY / 17
Atipamezole or its satlsPDL I DEC / 13
Atomoxetine or its saltsPDL I DEC / 13
Atorvastatin or its saltsPDL I DEC / 13
AtovaquonePDL I DEC / 13
Atracurium besilatePDL I DEC / 13
Atropine or its saltsPDL

including but not limited to atropine sulphate, in ophthalmic or parenteral preparations

I DEC / 13
Attapulgite active U
Avermectin or its derivativesPDL

including but not limited to ivermectin, selamectin, doramectin

I DEC / 13
Avilamycin or its salts or derivativesPDL I MAR / 14
Axitinib or its salts or derivativesPDL I DEC / 13
Azacitidine or its salts or derivativesPDL I DEC / 13
Azacyclonol or its saltsPDL I DEC / 13
AzaribinePDL I DEC / 13
Azathioprine or its saltsPDL I DEC / 13
Azatidine or its saltsPDL

including but not limited to azatadine

I DEC / 13
Azelaic acidPDL I DEC / 13
Azelastine or its saltsPDL I DEC / 14
Azilsartan medoxomil or its salts or derivativesPDL I DEC / 13
Azithromycin or its salts or derivativesPDL I DEC / 13
Aztreonam or its saltsPDL I DEC / 13
Bacillus Calmette-Guerin vaccine I FEB / 02
Bacitracin and its salts

for topical use

U SEP / 98
Bacitracin and its salts and derivatives for parenteral use I SEP / 98
Bacitracin and its salts and derivatives. for ophthalmic use III JUN / 06
Baclofen or its saltsPDL I DEC / 13
Bambuterol or its saltsPDL I DEC / 13
BarbitalC2 I JUN / 02
Barbituric AcidC2 I JUN / 02
BasiliximabPDL I DEC / 13
Bazedoxifene or its saltsPDL I DEC / 14
BecaplerminPDL I DEC / 13
BelimumabPDL I DEC / 13
Belladonna alkaloids and their salts and derivatives for topical use III SEP / 98
Belladonna alkaloids, and their salts and derivatives except in preparations for topical use or in trace amounts in homeopathic preparations II SEP / 98
BemegridePDL I DEC / 13
Benactyzine or its saltsPDL I DEC / 13
Benazepril or its salts or derivativesPDL

including but not limited to benazepril hydrochloride

I DEC / 13
Bendamustine or its salts or derivativesPDL

including but not limited to bendamustine hydrochloride

I DEC / 13
Bendazac or its saltsPDL I DEC / 13
Benoxaprofen or its saltsPDL I DEC / 13
Benoxinate hydrochloride oxybuprocaine for ophthalmic or parenteral use II SEP / 98
Benserazide or its saltsPDL I DEC / 13
Bentiromide II SEP / 98
Benzalkonium and its salts liquid preparations in concentrations of more than 2% II SEP / 98
BenzethidineN I JUN / 02
Benzethonium chloride liquid preparations in concentrations of more than 1% II SEP / 98
Benzocaine and its salts for parenteral or ophthalmic use II SEP / 98
Benzocaine and its salts. for topical use on mucous membranes for teething III SEP / 98
Benzocaine and its salts.. for topical application on the skin U
Benzonatate III SEP / 98
Benzoyl peroxidePDL

in concentrations greater than 5% or when sold in combination with another medicinal ingredient

I DEC / 13
Benzoyl peroxide. preparations of 5% or less as a single ingredient U MAY / 08
BenzphetamineC1 I JUN / 02
Benztropine or its saltsPDL

including but not limited to benzatropine

I DEC / 13
Benzydamine or its saltsPDL I DEC / 13
Benzyl benzoate II SEP / 98
BenzylmorphineN I JUN / 02
Bepotastine or its salts or derivativesPDL I NOV / 16
BeractantPDL I DEC / 13
Berberis vulgaris Barberry III SEP / 98
Besifloxacin or its saltsPDL I DEC / 13
BetacetylmethadolN I JUN / 02
Betahistine or its saltsPDL I DEC / 13
Betaine or its saltsPDL

for human use, when sold or recommended for the treatment of homocystinuria

I DEC / 13
Betaine or its salts.

for veterinary use

I DEC / 13
BetameprodineN I JUN / 02
BetamethadolN I JUN / 02
BetaprodineN I JUN / 02
Betaxolol or its saltsPDL I DEC / 13
Bethanechol chloridePDL I DEC / 13
Bethanidine or its saltsPDL I DEC / 13
BevacizumabPDL I DEC / 13
Bezafibrate or its salts or derivativesPDL I DEC / 13
BicalutamidePDL I DEC / 13
Bilastine or its salts or derivativesPDL I AUG / 16
Bile salts U
Bioflavanoids U
Biperiden or its saltsPDL I DEC / 13
Bisacodyl when sold in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50mg of bisacodyl U JAN / 14
Bisacodyl and its salts

(except when sold in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl)

III JAN / 14
Bishydroxycoumarin or its salts or derivativesPDL I DEC / 13
Bisoprolol or its saltsPDL I DEC / 13
Bitolterol or its saltsPDL I DEC / 13
BivalirudinPDL I DEC / 13
BleomycinPDL I DEC / 13
BlinatumomabPDL I AUG / 16
Boceprevir or its derivativesPDL I DEC / 13
BolandiolC3 I JUN / 02
BolasteroneC3 I JUN / 02
BolazineC3 I JUN / 02
BoldenoneC3 I JUN / 02
BolenolC3 I JUN / 02
Boric acid and its salts in preparations for systemic use, or ophthalmic preparations in concentrations over 2%[Note: does not apply to contact lens solutions intended to be rinsed off prior to insertion in the eye] II DEC / 98
Boric acid and its salts. in ophthalmic preparations in concentrations up to and including 2%, and in contact lens solutions intended to be rinsed off prior to insertion into the eye U DEC / 98
BortezomibPDL I DEC / 13
Bosentan or its salts or derivativesPDL I DEC / 13
Bosutinib or its saltsPDL

including but not limited to Bosutinib methanoate

I AUG / 14
Botulinum toxinPDL

including but not limited to onabotulinumtoxin A, incobotulinumtoxin A, abobotulinumtoxin A, rimabotulinumtoxin B

I DEC / 13
Brentuximab vedotinPDL I DEC / 13
Bretylium tosylatePDL I DEC / 13
Brexpiprazole or its saltsPDL I APR / 17
Brimonidine or its saltsPDL I DEC / 13
Brivaracetam or its derivativesPDL I AUG / 16
BromalPDL I DEC / 13
Bromal hydratePDL I DEC / 13
Bromazepam and its saltsTS I SEP / 98
BrometonePDL I DEC / 13
Bromfenac or its saltsPDL I MAY / 15
BromisovalPDL I DEC / 13
Bromocriptine or its saltsPDL I DEC / 13
BromoformPDL I DEC / 13
Brompheniramine and its salts as a single entity for the treatment of allergies III JAN / 03
Brompheniramine and its salts. in combination products for the relief of cough and cold symptoms U JAN / 03
BrotizolamTS I JUN / 02
Buclizine II SEP / 98
Bufexamac II SEP / 98
Bumetanide or its salts or derivativesPDL I DEC / 13
Bupivacaine and its salts for topical use on mucous membranes except lozenges III SEP / 98
Bupivacaine and its salts for parenteral or ophthalmic use II SEP / 98
BuprenorphineN I JUN / 02
Bupropion or its saltsPDL I DEC / 13
Buserelin or its saltsPDL I DEC / 13
Buspirone or its saltsPDL I DEC / 13
BusulfanPDL I DEC / 13
ButabarbitalC2 I JUN / 02
Butacaine and its salts for ophthalmic or parenteral use II SEP / 98
ButalbitalC2 I JUN / 02
ButallylonalC2 I JUN / 02
Butaperazine or its saltsPDL I DEC / 13
Butenafine 1% cream U SEP / 99
ButethalC2 I JUN / 02
Butoconazole or its saltsPDL I DEC / 13
Butorphanol and any salt thereofC2 I JUN / 02
Butyl chloral hydratePDL I DEC / 13
Cabergoline or its saltsPDL I DEC / 13
CalcipotriolPDL I DEC / 13
CalcitoninPDL I DEC / 13
CalcitriolPDL I DEC / 13
Calcium bromidePDL I DEC / 13
Calcium bromolactobionatePDL I DEC / 13
Calcium carbimidePDL I DEC / 13
Calcium chloride in injectable form for parenteral nutrition I JAN / 03
Calcium disodium edetate II SEP / 98
Calcium gluconate in injectable form for parenteral nutrition I JAN / 03
Calcium polycarbophil III SEP / 98
Calcium salts when sold for the treatment of hyperphosphatemiaPDL I DEC / 13
CalusteroneC3 I JUN / 02
CamazepamTS I JUN / 02
Camphor in oleaginous vehicles and in liquid forms in concentrations greater than 11% II OCT / 98
Camphor. in oleaginous vehicles and in liquid forms in concentrations up to and including 11% U OCT / 98
CanagliflozinPDL I JUL / 14
CanakinumabPDL I DEC / 13
Candesartan or its salts or derivatives

including but not limited to candesartan cilexetil

I DEC / 13
Candicidin or its salts or derivativesPDL I DEC / 13
CannabisN

its preparations and derivatives, as listed in the schedules to the Controlled Drugs and Substances Act and the Narcotic Control Regulations

I JUL / 15
Cantharides, their preparations and derivatives II SEP / 98
Capreomycin or its salts ir deriviativesPDL I DEC / 13
Caprylic acid except when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations greater than 30% and/or with a pH lower than 3.0 for a use other than to be applied to warts, corns or calluses U DEC / 14
Capsaicin U AUG / 97
Captodiamine or its saltsPDL I DEC / 13
Captopril or its saltsPDL I DEC / 13
CarbacholPDL I DEC / 13
CarbamazepinePDL I DEC / 13
Carbenoxolone or its saltsPDL I DEC / 13
Carbetocin or its saltsPDL I DEC / 13
Carbidopa or its saltsPDL I DEC / 13
CarbimazolePDL I DEC / 13
Carbinoxamine or its salts III SEP / 98
CarbocisteinePDL I DEC / 13
Carbomycin or its salts or derivativesPDL I DEC / 13
CarboplatinPDL I DEC / 13
CarbromalPDL I DEC / 13
CarfentanilN I JUN / 02
CarfilzomibPDL I AUG / 16
Carglumic acid or its salts or derivativesPDL I JUN / 15
CarisoprodolPDL I DEC / 13
CarmustinePDL I DEC / 13
Carphenazine or its saltsPDL I DEC / 13
Carprofen or its salts or derivativesPDL I DEC / 13
Carvedilol and its saltsPDL I DEC / 13
Casanthranol III SEP / 98
Cascara sagrada or its extracts or derivatives U AUG / 97
Caspofungin or its salts or derivativesPDL I DEC / 13
CatumaxomabPDL I DEC / 13
Celecoxib or its saltsPDL I DEC / 13
Cephalosporin C or its salts or derivativesPDL

including but not limited to: cefdinir, cefepime, cefonicide, cefoperazone, cefpodoxime proxetil, cefprozil, ceftazidime, ceftibuten, ceftolozane, cefuroxime, lorcarbef.

I APR / 17
Cerapon III SEP / 98
Ceritinib or its saltsPDL I MAY / 15
Cerivastatin or its saltsPDL I DEC / 13
Certolizumab pegolPDL I DEC / 13
Cetirizine or its saltsPDL

see hydroxyzine or its salts or derivatives

I DEC / 13
Cetirizine or its salts. in concentrations of 10 mg equivalent to 8.5 mg or less of cetirizine base per dosage unit, in products marketed for pediatric use (under 12 years of age) III JUL / 02
Cetirizine or its salts..

in concentrations of 10mg equivalent to 8.5mg or less of cetirizine base per dosage unit) in products marketed for adult use (age 12 and over)

U JUL / 02
Cetrorelix or its saltsPDL I DEC / 13
CetuximabPDL I DEC / 13
Charcoal (activated) except for use in poisoning treatment U JUN / 98
Charcoal [activated] for use in poisoning treatment II SEP / 98
Chlophedianol and its salts III SEP / 98
ChloralPDL I DEC / 13
Chloral hydratePDL I DEC / 13
ChloralformamidePDL I DEC / 13
ChloralimidePDL I DEC / 13
Chlorambucil or its salts or derivativesPDL I DEC / 13
Chloramphenicol or its salts or derivativesPDL I DEC / 13
Chlorcyclizine or its saltsPDL

except in preparations for external use

I DEC / 13
Chlordiazepoxide and its saltsTS I SEP / 98
Chlorhexidine or its saltsPDL

for human use when used as a topical oral preparation

I DEC / 13
Chlorisondamine or its saltsPDL I DEC / 13
ChlormezanonePDL I DEC / 13
Chloroprocaine and its salts for parenteral or ophthalmic use II SEP / 98
Chloroprocaine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
Chloroquine or its saltsPDL I DEC / 13
Chlorothiazide or its salts or derivatives

for human use

I DEC / 13
Chlorpheniramine and its salts and preparations U AUG / 97
Chlorphentermine and any salt thereofC2 I JUN / 02
Chlorpromazine or its saltsPDL

for human use

I DEC / 13
ChlorpropamidePDL I DEC / 13
Chlorprothixene or its saltsPDL I DEC / 13
Chlorzoxazone and its salts III SEP / 98
Cholecystokinin II SEP / 98
Cholera vaccine except oral, inactivated, when used for prophylaxis against travellers' diarrhea & due to enterotoxigenic escherichia coli (ETEC) I JAN / 04
Cholera vaccine (oral, inactivated) when used for prophylaxis against travellers' diarrhea & due to enterotoxigenic escherichia coli (ETEC) II JAN / 04
Cholestyramine resinPDL

for human use

I DEC / 13
Choline bitartrate parenteral II SEP / 98
Choline salicylatePDL

when sold in combination with magnesium salicylate

I DEC / 13
Choline theophyllinatePDL I DEC / 13
Choriogonadotropin alfaPDL I DEC / 13
Chromium Chloride (chromic chloride) in injectable form for parenteral nutrition I JAN / 03
Chymopapain parenteral II SEP / 98
Chymotrypsin parenteral and ophthalmic II SEP / 98
Ciclopirox or its saltsPDL I DEC / 13
Cilastatin or its saltsPDL I DEC / 13
Cilazapril or its salts or derivativesPDL I DEC / 13
Cimetidine or its saltsPDL

for veterinary use

I DEC / 13
Cimetidine or its salts.

except when sold in concentrations of 200 milligrams or less per oral dosage unit and indicated for the treatment of heartburn

I DEC / 13
Cimetidine or its salts..

when sold in concentrations of 100 mg or less per dosage unit and indicated for the treatment of heartburn

III DEC / 13
Cinacalcet or its saltsPDL I DEC / 13
Cinchocaine (dibucaine) and its salts for ophthalmic or parenteral use II SEP / 98
Cinchophene or its saltsPDL I DEC / 13
Cinnamedrine U
CinoxacinPDL I DEC / 13
Ciprofloxacin or its saltsPDL I DEC / 13
Cisapride or its saltsPDL I SEP / 98
Cisatracurium besilatePDL I DEC / 13
CisplatinPDL I DEC / 13
Citalopram or its saltsPDL I DEC / 13
Cladribine or its salts or derivativesPDL I DEC / 13
Clarithromycin or its salts or derivativesPDL

for human use

I DEC / 13
Clemastine and its salts III SEP / 98
Clenbuterol or its saltsPDL I DEC / 13
Clevidipine or its saltsPDL I DEC / 13
Clidinium and its salts II SEP / 98
Clindamycin or its salts or derivativesPDL I DEC / 13
Clobazam and its saltsTS I SEP / 98
Clobetasone butyrate when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin II OCT / 06
Clodronic acid or its saltsPDL I DEC / 13
ClofarabinePDL I DEC / 13
ClofibratePDL I DEC / 13
Clomiphene or its saltsPDL I DEC / 13
Clomipramine or its saltsPDL I DEC / 13
Clonazepam and its saltsTS I SEP / 98
Clonidine or its saltsPDL I DEC / 13
ClonitazeneN I JUN / 02
Clopidogrel or its saltsPDL I DEC / 13
ClorazepateTS I JUN / 02
Clorazepic acid or its saltsPDL I DEC / 13
Closantel or its saltsPDL

for veterinary use, including but not limited to closantel sodium

I AUG / 16
ClostebolC3 I JUN / 02
Clotiazepam and any salt thereofTS I JUN / 02
Clotrimazole and its salts.. for human use in preparations for topical use U DEC / 13
Clotrimazole or its saltsPDL

for human use, except in preparations for topical or vaginal use

I DEC / 13
Clotrimazole or its salts.

for human use in preparations for intra-vaginal use

III DEC / 13
CloxazolamTS I JUN / 02
Clozapine or its saltsPDL I DEC / 13
Coal tar in concentrations of more than 10% II SEP / 98
Coal tar. in concentrations up to and including 10% U
Cobimetinib or its saltsPDL I AUG / 16
Coca leavesN I JUN / 02
Cocaine (benzoylmethylecgonine)N Subject to Section 2 (2) of the Narcotic Control Regulations (NCR) and Section J of the Food and Drug Regulations (FDR) as of 23 October 2013. I JUN / 02
CodeineN I JUN / 02
Codeine and its salts in preparations exempted from the Regulations to the Controlled Drugs and Substances Act II SEP / 98
CodoximeN I JUN / 02
ColchicinePDL I DEC / 13
Colesevelam or its saltsPDL

including but not limited to colesevelam hydrochloride

I DEC / 13
Colestipol or its saltsPDL I DEC / 13
Colfosceril or its derivativesPDL I DEC / 13
Colistin or its salt or derivativesPDL

including but not limited to colistimethate

I DEC / 13
CollagenasePDL

when recommend for the debridement of severe burns and skin ulcers

I DEC / 13
Copper chloride (cupric chloride) in injectable form for parenteral nutrition I JAN / 03
Copper sulfate in injectable form for parenteral nutrition I JAN / 03
Crizotinib or its salts or derivativesPDL I DEC / 13
Cromoglicic (cromoglycic) acid or its saltsPDL

except sodium cromoglicate (cromoglycate) in solutions for ophthalmic or nasal use in concentrations of 2% or less [*see sodium cromoglicate (cromoglycate)]

I DEC / 13
Crotamiton II SEP / 98
Cyclandelate II SEP / 98
Cyclazocine and its salts II SEP / 98
CyclizinePDL

for human use

I DEC / 13
CyclobarbitalC2 I JUN / 02
Cyclobenzaprine or its saltsPDL I DEC / 13
Cyclomethacaine and its salts for ophthalmic or parenteral use II SEP / 98
CyclopalC2 I JUN / 02
Cyclopentamine and its salts II SEP / 98
Cyclopentolate or its salts except in products for ophthalmic or parenteral use II SEP / 98
Cyclopentolate or its saltsPDL

in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada

I DEC / 13
CyclophosphamidePDL I DEC / 13
CycloserinePDL I DEC / 13
CyclosporinePDL

including but not limited to ciclosporin

I DEC / 13
Cyproheptadine and its salts II SEP / 98
Cyproterone acetatePDL

including but not limited to cyproterone acetate

I DEC / 13
Cysteamine (Mercaptamine) or its saltsPDL I AUG / 17
Cytarabine or its saltsPDL I DEC / 13
Cytomegalovirus immune globulins I FEB / 02
Dabigatran or its salts or derivativesPDL

including but not limited to dabigatran etexilate

I DEC / 13
Dabrafenib or its saltsPDL I DEC / 13
DacarbazinePDL I DEC / 13
Daclatasvir or its saltsPDL I OCT / 15
DaclizumabPDL I DEC / 13
Daclizumab betaPDL I FEB / 17
DactinomycinPDL I DEC / 13
Dalfopristin or its saltsPDL I DEC / 13
Dalteparin or its saltsPDL I DEC / 13
Danaparoid or its salts or derivativesPDL I DEC / 13
DanazolPDL I DEC / 13
Danofloxacin or its saltsPDL I DEC / 13
Danthron III SEP / 98
Dantrolene or its saltsPDL I DEC / 13
Dapagliflozin or its derivativesPDL I MAR / 15
Dapiprazole or its saltsPDL I DEC / 13
DaptomycinPDL I DEC / 13
DaratumumabPDL I AUG / 16
Darifenacin or its saltsPDL I DEC / 13
DarunavirPDL I DEC / 13
Dasabuvir or its saltsPDL I MAR / 15
DasatanibPDL I DEC / 13
Daunorubicin or its saltsPDL I DEC / 13
Debrisoquin or its saltsPDL I DEC / 13
DeferasiroxPDL I DEC / 13
Deferiprone or its derivativesPDL I MAR / 15
Deferoxamine or its saltsPDL I DEC / 13
Degarelix or its salts or derivativesPDL I DEC / 13
Dehydrocholic acid and its salts III SEP / 98
Delavirdine or its saltsPDL I DEC / 13
DelorazepamTS I JUN / 02
DenosumabPDL I DEC / 13
Deoxycholic acid or its saltsPDL

when used in an injectable form

I OCT / 15
Deoxycholic acid or its salts.

except when used in an injectable form

III OCT / 15
DeracoxibPDL I DEC / 13
Derquantel or its saltsPDL

for veterinary use

I AUG / 16
Deserpidine or its alkaloids or saltsPDL I DEC / 13
DesfluranePDL I DEC / 13
Desipramine or its saltsPDL I DEC / 13
Desloratadine and its salts and preparations. in products marketed for paediatric use - under 12 years of age III SEP / 05
Desloratadine and its salts and preparations.

in products marketed for adult use - 12 years and older

U SEP / 05
Desmopressin or its saltsPDL I DEC / 13
DesomorphineN I JUN / 02
Desoxyribonuclease [pancreatic dornase] II SEP / 98
Desvenlafaxine or its saltsPDL

including but not limited to desvenlafaxine succinate

I DEC / 13
Detomidine or its saltsPDL I DEC / 13
Dexbrompheniramine and its salts III SEP / 98
Dexchlorpheniramine and its salts III SEP / 98
Dexrazoxane or its saltsPDL I DEC / 13
Dextromethorphan and its salts except in oral dosage forms in package sizes containing no more than 300mg DM base or 409.3 DM hydrobromide III AUG / 02
Dextromethorphan and its salts. in oral dosage forms in package sizes containing no more than 300 mg DM base or 409.3 DM hydrobromide U AUG / 02
DextromoramideN I JUN / 02
DextropropoxypheneN I JUN / 02
Dextrose sclerosing agents II SEP / 98
Dextrose injection concentrated solutions for parenteral injection I JAN / 03
DiampromideN I JUN / 02
Diazepam and its saltsTS I SEP / 98
Diazoxide or its saltsPDL I DEC / 13
Dibotermin alfaPDL

for veterinary use

I FEB / 14
Dichloroacetic acidPDL I DEC / 13
Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days - in concentrations greater than 1.16% and less than or equal to 2.32% - in package sizes containing greater than 2.6g of diclofenac diethylamine II AUG / 14
Diclofenac diethylamine.

when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days - in concentrations greater than 1.16% and less than or equal to 2.32% - in package sizes containing no more than 2.6g of diclofenac diethylamine

III AUG / 14
Diclofenac diethylamine..

when sold as a single medicinal ingredient for topical use on the skin in concentrations of not more than 1.16% for not more than 7 days

U AUG / 14
Diclofenac or its saltsPDL

including (but not limited to): diclofenac diethylamine, diclofenac sodium, diclofenac potassium, except when sold as a single medicinal ingredient for topical use on the skin in a concentration equivalent to 2% or less of diclofenac for not more than 7 days

I AUG / 14
Dicyclomine and its salts except for topical use and lozenges II SEP / 98
Didanosine or its salts or derivativesPDL I DEC / 13
DiethylbromacetamidePDL I DEC / 13
Diethylcarbamazine or its saltsPDL I DEC / 13
Diethylpropion and any salt thereofC2 I JUN / 02
Diethylstilbestrol or its salts or derivativesPDL I DEC / 13
DiethylthiambuteneN I JUN / 02
DifenoxinN I JUN / 02
Difloxacin or its salts or derivativesPDL I DEC / 13
Diflunisal or its saltsPDL I DEC / 13
Digestive enzymes from plant sources U SEP / 99
Digoxin immune FabF1 ovine I SEP / 98
DihydrocodeineN I JUN / 02
DihydromorphineN I JUN / 02
Dihydroquinidine and its salts except phenylbarbiturate II SEP / 98
Dihydrostreptomycin and its salts and derivativesF2 I SEP / 98
DihydrotachysterolF1 I SEP / 98
DiiodohydroxyquinF1 except in preparations for topical use on the skin I SEP / 98
Diiodohydroxyquin for topical use on the skin II SEP / 98
Diltiazem and its saltsF1 I SEP / 98
Dimenhydrinate and its salts for parenteral use II SEP / 98
Dimenhydrinate and its salts. for oral or rectal use [Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, dimenhydrinate products should not be located in a self-selection area of the pharmacy]. III APR / 99
DimenoxadolN I JUN / 02
DimepheptanolN I JUN / 02
DimercaprolF1 I SEP / 98
Dimethothiazine III SEP / 98
Dimethyl sulfoxideF1 for veterinary use or when sold for the treatment of interstitial cystitis or scleroderma in humans I DEC / 11
DimethylaminodiphenylbutanonitrileN I JUN / 02
DimethylthiambuteneN I JUN / 02
Dimeticone 100 cSt solution 50% w/w for topical use in the treatment of head lice III JAN / 13
Dinitrophenol or its salts or derivativesPDL I DEC / 13
Dioxaphetyl butyrateN I JUN / 02
Diperodon and its salts except for topical use II SEP / 98
Diphenhydramine and its salts and preparations for parenteral use II SEP / 98
Diphenhydramine and its salts and preparations. except for parenteral or topical use III SEP / 98
Diphenhydramine and its salts and preparations.. for topical use in concentrations of greater than 2% II MAY / 06
Diphenhydramine and its salts and preparations... for topical use in concentrations of 2% or less when sold in containers of greater than 300 mg of diphenhydramine hydrochloride III MAY / 06
Diphenhydramine and its salts and preparations... for topical use in concentrations of 2% or less when sold in containers of 300 mg or less of diphenhydramine hydrochloride U OCT / 09
Diphenidol and its saltsF1 I SEP / 98
DiphenoxylateN I JUN / 02
DiphenylhydantoinF1 phenytoin and its salts I SEP / 98
Diphenylmorpholinoisovaleric acidN I JUN / 02
Diphenylpyraline III SEP / 98
Diphtheria toxoid II DEC / 98
DipipanoneN I JUN / 02
Dipivefrin and its saltsF1 I SEP / 98
Diprophylline and its saltsF1 I SEP / 98
DipyridamoleF1 I SEP / 98
DirithromycinF2 I SEP / 98
DirlotapidePDL I DEC / 13
Disopyramide and its saltsF1 I SEP / 98
DisulfiramF1 I SEP / 98
Dithranol Anthralin II SEP / 98
Dobutamine and its saltsF1 I SEP / 98
Docetaxel and its derivativesF1 I SEP / 98
Docosanol 10% for topical use U OCT / 02
Docusate and its salts U
Dolasetron and its saltsF1 I SEP / 98
DomperidoneF1 I SEP / 98
Donepezil and its saltsF1 I SEP / 98
Dopamine and its saltsF1 when sold for administration by injection I DEC / 11
Dornase alfaF1 I SEP / 98
Dorzolamide and its saltsF1 I SEP / 98
Doxacurium chlorideF1 I SEP / 98
DoxapramF1 I SEP / 98
Doxazosin and its saltsF1 I SEP / 98
Doxepin and its saltsF1 I SEP / 98
Doxercalciferol and its derivativesF1 I OCT / 03
Doxorubicin and its saltsF1 I SEP / 98
Doxycycline or its salts or derivativesPDL

including but not limited to doxycycline hyclate, doxycycline monohydrate

I DEC / 13
Doxylamine and its salts except those sold for nausea and vomiting of pregnancy III SEP / 98
Doxylamine and its saltsF1 when sold or recommended for use in the nausea or vomiting of pregnancy I SEP / 98
Droperidol and its saltsF1 I SEP / 98
DrostanoloneC3 I JUN / 02
DrotebanolN I JUN / 02
DrotrecoginF1 I JUN / 06
DulaglutidePDL I JAN / 16
Duloxetine and its saltsF1 I MAY / 09
DutasterideF1 I JUN / 06
Dyclonine except for topical use on mucous membranes II SEP / 98
Dyclonine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
EcgonineN I JUN / 02
Econazole and its saltsF1 I SEP / 98
Ecothiophate and its saltsF2 I SEP / 98
Ectylurea and its saltsF1 I SEP / 98
EculizumabF1 I MAR / 11
Edoxaban or its saltsPDL I FEB / 17
Edrophonium chlorideF1 I SEP / 98
EfavirenzF1 I MAY / 00
Eflornithine and its salts and derivativesF1 I JUL / 03
Elbasvir or its saltsPDL I AUG / 16
Electrolyte solutions for oral rehydration III SEP / 98
Eletriptan and its saltsF1 I FEB / 07
Eliglustat or its saltsPDL I MAY / 17
Elosulfase alfaPDL I AUG / 14
ElotuzumabPDL I AUG / 16
Eltrombopag or its saltsPDL

including but not limited to eltrombopag olamine

I DEC / 13
Eluxadoline or its saltsPDL I APR / 17
EmbutramideF1 I SEP / 98
Emedastine and its saltsF1 I SEP / 99
EmpagliflozinPDL I OCT / 15
EmtricitabineF1 I FEB / 07
EmylcamateF1 I SEP / 98
Enalaprilat and its salts and derivativesF1 I SEP / 98
Encephalitis vaccine (Japanese) I FEB / 02
EnestebolC3 I JUN / 02
EnfluraneF1 I SEP / 98
EnfuvirtideF1 I JUN / 06
Enoxaparin and its saltsF1 I SEP / 98
EnrofloxacinF1 I SEP / 98
EntacaponeF1 I JUL / 03
EntecavirF1 I OCT / 07
Ephedrine and its salts in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion. I FEB / 02
Ephedrine and its salts in combination products in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. III APR / 06
Ephedrine and its salts in single entity products. in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. II APR / 06
Epinephrine and its salts in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens II SEP / 99
Epinephrine and its salts. other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens I SEP / 99
Epirubicine and its saltsF1 I SEP / 98
EpitiostanolC3 I JUN / 02
EplerenonePDL I DEC / 13
EpsiprantelF1 I MAY / 00
Ergot alkaloids and their saltsF2 I SEP / 98
Eribulin or its salts or derivativesPDL

including but not limited to eribulin mesylate

I DEC / 13
Erlotinib and its saltsF1 I OCT / 07
Ertapenem and its saltsF1 I JUN / 06
Erythrityl tetranitrate I SEP / 98
Erythromycin and its salts and derivativesF2 I SEP / 98
ErythropoietinF1 I SEP / 98
Escitalopram and its saltsF1 I FEB / 07
Esdepallethrin/piperonyl butoxide II SEP / 98
Eslicarbazepine acetatePDL I AUG / 14
Esmolol and its saltsF1 I SEP / 98
Esomeprazole or its salts except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole I AUG / 16
Esomeprazole or its salts. when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole II AUG / 16
Estazolam and its saltsTS I SEP / 98
Estramustine and its saltsF1 I SEP / 98
EtanerceptF1 I JUL / 03
Ethacrynic acidF1 I SEP / 98
Ethambutol and its saltsF1 I SEP / 98
Ethanolamine oleate II SEP / 98
EthchlorvynolTS I SEP / 98
EthinamateTS I SEP / 98
Ethionamide and its saltsF1 I SEP / 98
Ethoheptazine and its salts II SEP / 98
Ethomoxane and its saltsF1 I SEP / 98
Ethopropazine hydrochlorideF1 profenamine and its salts I SEP / 98
Ethotoin and its saltsF1 I SEP / 98
Ethyl Chloride except in trace amounts II SEP / 98
Ethyl LoflazepateTS I JUN / 02
Ethyl trichloramateF1 I SEP / 98
EthylestrenolC3 I JUN / 02
EthylmethylthiambuteneN I JUN / 02
EthylmorphineN I JUN / 02
Ethylpapaverine and its salts I SEP / 98
Etidronic acid and its saltsF1 I SEP / 98
Etodolac and its salts and derivativesF1 I SEP / 98
EtonitazeneN I JUN / 02
Etoposide and its derivativesF1 I SEP / 98
EtorphineN I JUN / 02
EtoxeridineN I JUN / 02
Etravirine and its saltsF1 I OCT / 09
EtretinateF1 I SEP / 98
Etryptamine and its saltsF1 I SEP / 98
Etymemazine and its saltsF1 I SEP / 98
EvolocumabPDL I JAN / 16
ExemestaneF1 I DEC / 02
Exenatide or its saltsPDL I DEC / 13
EzetimibeF1 I JUN / 06
Famciclovir and its saltsF1 I SEP / 98
Famotidine and its saltsF1 except when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn I FEB / 07
Famotidine and its salts. when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 600 mg of famotidine III MAY / 08
Famotidine and its salts.. when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 600 mg of famotidine U FEB / 07
Febuxostat or its salts or derivativesPDL I DEC / 13
Felodipine and its saltsF1 I SEP / 98
Fenetylline and any salt thereofC5 I JAN / 03
Fenfluramine or its saltsPDL

including but not limited to dexfenfluramine

I DEC / 13
FenofibrateF1 I SEP / 98
Fenoprofen and its saltsF1 I SEP / 98
Fenoterol and its saltsF1 I SEP / 98
FenproporexTS I JUN / 02
FentanylN I JUN / 02
Fexofenadine hydrochloride in products marketed for adult use (12 years and older) U APR / 07
Fexofenadine hydrochloride. in products marketed for paediatric use (under 12 years of age) III APR / 07
Fibrin II SEP / 98
Fibrinolysin II SEP / 98
FilgrastimF1 I SEP / 98
Finafloxacin or its salts or its derivativesPDL I AUG / 16
FinasterideF1 I SEP / 98
Fingolimod or its salts or derivativesPDL

including but not limited to fingolimod hydrochloride

I DEC / 13
FirocoxibPDL I DEC / 13
Flavoxate and its saltsF1 I SEP / 98
Flecainide and its saltsF1 I SEP / 98
Fleroxacin and its salts and derivativesF1 I SEP / 98
FloctafenineF1 I SEP / 98
Florfenicol and its derivativesF1 I SEP / 98
FluconazoleF1 except when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis I MAR / 10
Fluconazole when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis, in package sizes containing no more than 150 mg of fluconazole III MAR / 10
FlucytosineF1 I SEP / 98
Fludarabine and its salts and derivativesF1 I SEP / 98
FludiazepamTS I JUN / 02
Flumazenil I SEP / 98
Flunarizine and its saltsF1 I SEP / 98
FlunitrazepamTS I JUN / 02
Flunixin and its salts and derivativesF1 I SEP / 98
Fluoride or its salts (see sodium fluoride)

in solid oral dosage forms containing more than 1 mg of fluoride ion

I SEP / 98
Fluoride or its salts (see sodium fluoride).

in oral preparations containing 1 mg or less of fluoride ion per dosage unit

III SEP / 98
Fluorouracil or its derivativesPDL

including but not limited to capecitabine, tegafur

I DEC / 13
Fluoxetine and its saltsF1 I SEP / 98
FluoxymesteroneC3 I JUN / 02
Flupentixol and its salts and derivativesF1 I SEP / 98
Fluphenazine and its saltsF1 I SEP / 98
FluralanerPDL I JUL / 14
Flurazepam and its saltsTS I SEP / 98
Flurbiprofen and its saltsF1 I SEP / 98
FluspirileneF1 I SEP / 98
FlutamideF1 I SEP / 98
Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing no more than 120 metered sprays III AUG / 16
Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing more than 120 metered sprays II AUG / 16
Fluvastatin and its salts and derivativesF1 I SEP / 98
Fluvoxamine and its saltsF1 I SEP / 98
Folic AcidF2 I DEC / 99
Folic acidF1 in preparations containing more than 1 mg of folic acid per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 1.0 mg folic acid I SEP / 98
Follicle stimulating hormoneF1 I SEP / 98
Fomepizole and its saltsF1 I JUL / 03
Fondaparinux sodiumF1 I JUN / 06
FormeboloneC3 I SEP / 98
Formestane and derivativesF1 I SEP / 98
Formoterol and its saltsF1 I JUN / 06
Foscarnet sodiumF1 I SEP / 98
Fosfomycin and its saltsF1 I SEP / 99
Fosinopril and its saltsF1 I SEP / 98
Fosphenytoin and its saltsF1 I SEP / 98
Fractar III SEP / 98
Framycetin and its salts and derivativesF2 I SEP / 98
Frovatriptan and its saltsF1 I FEB / 07
FulvestrantF1 I SEP / 06
Furaltadone and its saltsF2 I SEP / 98
FurazabolC3 I SEP / 98
Furazolidone and its saltsF2 I SEP / 98
FurethidineN I JUN / 02
FurosemideF2 I SEP / 98
Fusidic acid and its saltsF1 I SEP / 98
Gabapentin and its salts and derivativesF1 I SEP / 98
Galantamine and its salts and derivativesF1 I OCT / 03
Gallamine triethiodideF1 I SEP / 98
Gallium and its saltsF1 I SEP / 98
Ganciclovir and its saltsF1 I SEP / 98
Ganirelix and its salts and derivativesF1 I MAY / 04
Gatifloxacin and its salts and derivativesF1 I JUL / 03
GefitinibF1 I SEP / 06
Gemcitabine and its saltsF1 I SEP / 98
Gemfibrozil and its saltsF1 I SEP / 98
Gemifloxacin and its saltsF1 I SEP / 06
Gentamicin and its salts and derivativesF1 I SEP / 98
Gentian Violet II DEC / 01
Glatiramer and its saltsF1 I SEP / 98
GliclazideF1 I SEP / 98
GlimepirideF1 I MAY / 04
GlipizideF1 I SEP / 98
Glucagon II SEP / 98
Glutamic acid and its salts gastric acidifiers U FEB / 99
GlutethimideF1 I SEP / 98
Glyburide and its salts and derivativesF1 I SEP / 98
Glyceroargentinate III SEP / 98
Glycopyronium bromidePDL

when used for inhalation

I DEC / 13
Glycopyrrolate or its salts except glycopyronium bromide when used for inhalation II DEC / 13
Gold or its salts or derivativesPDL

including but not limited to aurothioglucose, auranofin and sodium aurothiomalate, when sold for administration by injection

I DEC / 13
GolimumabF1 I MAR / 11
Gonadorelin and its saltsF1 I SEP / 98
Gonadotropin, chorionicF1 human I SEP / 98
Gonadotropin, serumF1 human I SEP / 98
Goserelin and its saltsF1 I SEP / 98
Gramicidin and its salts for topical use U
Gramicidin and its salts and derivatives for ophthalmic use III JUN / 06
Granisetron and its saltsF1 I SEP / 98
GrazoprevirPDL I AUG / 16
Grepafloxacin and its salts and derivativesF1 I SEP / 99
Griseofulvin and its salts and derivativesF2 I SEP / 98
Guaifenesin U
Guanethidine and its saltsF1 I SEP / 98
Haemophilus influenzae type B vaccine II DEC / 98
Halazepam and its saltsTS I SEP / 98
Halofantrine and its saltsF1 I SEP / 98
HaloperidolF1 I SEP / 98
Haloprogin III SEP / 98
HalothaneF1 I SEP / 98
HaloxazolamTS I JUN / 02
Heparin and its salts for topical use III SEP / 98
Heparin and its salts. except for topical use II SEP / 99
Hepatitis A vaccine I FEB / 02
Hepatitis B Adult vaccine I FEB / 02
Hepatitis B Pediatric vaccine II DEC / 98
Hepatitis B immune globulin I FEB / 02
HeptabarbitalC2 I JUN / 02
Hetastarch and its derivativesF1 I SEP / 06
Hexachlorophene and its saltsF1 I SEP / 98
Hexacyclonate sodiumF1 I SEP / 98
Hexamethonium and its saltsF1 I SEP / 98
HexethalC2 I JUN / 02
HexobarbitalC2 I JUN / 02
Histamine and its salts except for topical use II SEP / 98
Histrelin and its saltsF1 I OCT / 07
Homatropine and its salts for oral use in concentrations of 2 mg or less per dosage unit II SEP / 98
Homatropine and its salts for ophthalmic or parenteral use or in preparations for oral use containing more than 2 mg per dosage unit I SEP / 98
Human insulinD II SEP / 98
Hyaluronic acid and its saltsF1 when sold or recommended for administration by intra-articular injection to horses I SEP / 98
Hyaluronic acid and its salts preparations in concentrations of 5% or more II SEP / 98
Hyaluronidase II SEP / 98
Hydralazine and its saltsF1 I SEP / 98
HydrocodoneN I JUN / 02
Hydrocortisone or hydrocortisone acetate

when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in children under 2 years of age

I DEC / 14
Hydrocortisone or hydrocortisone acetate.

when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in adults and children 2 years of age and over in package sizes containing more than 30 g

I DEC / 14
Hydrocortisone or hydrocortisone acetate..

when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in adults and children 2 years of age and over in package sizes containing no more than 30 g

III DEC / 14
HydromorphinolN I JUN / 02
HydromorphoneN I JUN / 02
Hydroquinone topical preparations II SEP / 99
Hydroxocobalamin or its saltsPDL

when recommended as an antidote for cyanide poisoning

I DEC / 13
Hydroxychloroquine and its saltsF1 I SEP / 98
Hydroxycoumarin or its derivativesPDL

including but not limited to acenocoumarol when sold or recommended as anticoagulants

I DEC / 13
Hydroxyephedrine and its salts II SEP / 98
HydroxypethidineN I JUN / 02
HydroxyureaF1 I SEP / 98
Hydroxyzine or its salts or derivativesPDL

including but not limited to cetirizine and hydroxyzine hydrochloride except cetirizine or its salts when sold in concentration greater than 8.5 milligrams cetirizine per unit dose

I DEC / 13
Hyoscine and its salts and derivatives [scopolamine] except Hyoscine butylbromide, when recommended for parenteral use II AUG / 16
Hyoscine butylbromidePDL

when recommended for parenteral use

I AUG / 16
Hyoscyamine and its salts and derivatives except for topical use II SEP / 98
IbafloxacinPDL I DEC / 13
Ibandronic acid and its saltsF1 I SEP / 06
Ibogaine or its salts or derivatives or analoguesPDL I MAY / 17
Ibrutinib or its saltsPDL I DEC / 14
Ibuprofen or its saltsPDL

except when sold in an oral dosage form that provides 400 mg or less per dosage unit or in a modified-release oral dosage form that provides 600 mg or less per dosage unit

I AUG / 16
Ibuprofen or its salts. when sold in an immediate release dosage form containing 400 mg or less per oral dosage unit (in package sizes exceeding 18,000 mg) III FEB / 12
Ibuprofen or its salts..

when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit

III AUG / 16
Ibuprofen or its salts... when sold in an immediate release dosage form containing 400 mg or less per oral dosage unit (in package sizes of up to 18,000 mg) U FEB / 12
Ibutilide and its salts and derivativesF1 I DEC / 02
Icatibant or its saltsPDL

including but not limited to Icatibant acetate

I AUG / 14
Idarubicin and its saltsF1 I SEP / 98
IdarucizumabPDL I AUG / 16
IdebenonePDL I DEC / 13
IdelalisibPDL I MAY / 15
IdoxuridineF1 I SEP / 98
IdursulfaseFR I FEB / 09
IfosfamideF1 I SEP / 98
Imatinib and its saltsF1 I OCT / 03
ImigluceraseF1 I SEP / 98
Imipenem and its salts and derivativesF1 I SEP / 98
Imipramine and its saltsF1 I SEP / 98
Imiquimod and its saltsF1 I MAY / 00
Immune globulin products I FEB / 02
Indacaterol or its salts or derivativesPDL I DEC / 13
Indapamide and its saltsF1 I SEP / 98
Indinavir and its saltsF1 I SEP / 98
IndomethacinF1 I SEP / 98
InfliximabF1 I JUL / 03
Influenza vaccine II DEC / 98
Inhaled human insulinF1 I JUN / 08
Inhaled human insulin.F1 I DEC / 08
InosiplexF1 I SEP / 98
Inositol niacinate U DEC / 98
InsulinD II SEP / 98
InterferonF1 I SEP / 98
Invermectin and its derivatives, for human use or for veterinary useF1 when sold for intramuscular injection into horses or for administration to dogs and cats I MAY / 04
Iodinated glycerol II SEP / 98
Iodine and its salts and derivatives except topical preparations or in oral doses of 1 mg or less per day II DEC / 98
Iodine and its salts and derivatives for topical use III SEP / 98
Iodochlorhydroxyquin for topical use II SEP / 98
IodochlorohydroxyquinF1 except in preparations for topical use on the skin I SEP / 98
Ipecac and its extracts and derivatives when used as an emetic II OCT / 98
Ipecac and its extracts and derivatives. for use other than as an emetic U OCT / 98
IpilimumabPDL I DEC / 13
Ipratropium and its saltsF1 I SEP / 98
Iproniazid and its saltsF1 I SEP / 98
Irbesartan and its saltsF1 I SEP / 99
Irinotecan and its saltsF1 I SEP / 98
Iron and its salts and derivatives in preparations with more than 30 mg elemental iron per solid dosage unit or 5 mL oral liquid II SEP / 98
Iron and its salts and derivatives. in preparations containing 30 mg or less elemental iron per solid dosage unit or 5 ml oral liquid U
Iron derivativesPDL

for human use, including but not limited to ferumoxytol for parenteral use only

I DEC / 13
Iron derivativesPDL

for veterinary use, including but not limited to ferumoxytol for all routes of administration but parenteral

I DEC / 13
Isocarboxazid and its saltsF1 I SEP / 98
IsofluraneF1 I SEP / 98
IsomethadoneN I JUN / 02
IsoniazidF1 I SEP / 98
Isopropamide and its salts I SEP / 98
Isopropyl myristate in concentration of 50%

for use in the treatment of head lice

III JUL / 07
IsoproterenolF1 Isoprenaline and its salts I SEP / 98
Isosorbide and its salts I SEP / 98
Isotretinoin and its saltsF1 I SEP / 98
Isoxsuprine and its saltsF1 I SEP / 98
Isradipine and its saltsF1 I SEP / 98
Itraconazole and its saltsF1 I SEP / 98
Ivabradine or its salts or derivativesPDL I FEB / 17
Ivermectin and its derivativesF1 for human use or for veterinary use when sold for intramuscular injection into horses or for administration to dogs and cats I MAY / 04
Ixazomib or its derivativesPDL I NOV / 16
IxekizumabPDL I AUG / 16
Kanamycin and its salts and derivativesF2 I SEP / 98
Ketamine and its saltsN I AUG / 05
Ketazolam and its saltsTS I SEP / 98
KetobemidoneN I JUN / 02
Ketoconazole and its saltsF1 except in preparations for topical use as a shampoo I SEP / 98
Ketoconazole and its salts. as a shampoo U
Ketoprofene and its saltsF1 I SEP / 98
Ketorolac and its saltsF1 I SEP / 98
Ketotifen and its saltsF1 I SEP / 98
Labetalol and its saltsF1 I SEP / 98
Lacosamide or its derivativesPDL I DEC / 13
Lactic acidPDL

when recommended for parenteral use as a tissue sclerosing agent

I DEC / 13
Lactic acid.

in preparations in concentrations of more than 10% except when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations greater than 30% and/or with a pH lower than 3.0 for a use other than to be applied to warts, corns or calluses

III DEC / 14
Lactulose III SEP / 98
Lamivudine and its saltsF1 I SEP / 98
Lamotrigine and its saltsF1 I SEP / 98
Lanreotide and its saltsF1 I MAY / 09
Lansoprazole and its saltsF1 I SEP / 98
Lanthanum salts.F1 when sold for the treatment of hyperphosphatemia I FEB / 08
Lapatinib and its saltsF1 I MAR / 11
LaronidaseF1 I APR / 07
Ledipasvir or its saltsPDL I DEC / 14
Lefetamine and any Salt thereofC4 I JAN / 03
Leflunomide and its saltsF1 I DEC / 01
LenalidomideF1 I MAY / 09
Lenvatinib or its saltsPDL I AUG / 16
LetrozoleF1 I SEP / 98
Leucovorin and its saltsF1 I SEP / 98
Leuprolide and its saltsF1 I SEP / 98
Levallorphane and its salts I SEP / 98
Levamisole and its saltsF2 I SEP / 98
Levargorphane and its salts II SEP / 98
LevetiracetamF1 I JUN / 06
Levobunolol and its saltsF1 I SEP / 98
Levocabastine and its salts and derivativesF1 I SEP / 98
Levocarnitine and its salts and derivativesF1 when sold for the treatment of primary or secondary levocarnitine deficiency I DEC / 11
Levodopa and its saltsF1 I SEP / 98
LevomethorphanN I JUN / 02
Levomilnacipran or its saltsPDL I JUN / 15
LevomoramideN I JUN / 02
Levonordefrine II SEP / 98
Levonorgestrel when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) II MAY / 15
Levonorgestrel. when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel III MAY / 15
LevophenacylmorphanN I JUN / 02
LevorphanolN I JUN / 02
LidocainePDL

when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher

I FEB / 14
Lidocaine and its salts for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges II SEP / 98
Lidocaine and its salts.

for otic use

III JUN / 06
Lidocaine and its salts..

for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]

U FEB / 14
Lidocaine and prilocaine eutectic mixture III FEB / 99
Linagliptin or its salts or derivativesPDL I DEC / 13
Lincomycin and its salts and derivativesF2 I SEP / 98
Lindane II SEP / 98
Linezolid and its saltsF1 I JUL / 03
Linezolid and its salts.F1 I JUN / 03
Liothyronine and its saltsF2 I SEP / 98
Lipid solutions in injectable form for parenteral nutrition I JAN / 03
Liraglutide or its saltsPDL I DEC / 13
Lisinopril and its salts and derivativesF1 I SEP / 98
Lithium and its saltsF1 I SEP / 98
Lixisenatide or its saltsPDL I JUN / 17
Lodoxamide and its salts and derivativesF1 I SEP / 98
Lomefloxacin and its saltsF1 I SEP / 98
Lomitapide or its saltsPDL I FEB / 14
LomustineF1 I SEP / 98
Loperamide and its salts in products marketed for adult use (12 years and older) U APR / 07
Loperamide and its salts. in products marketed for paediatric use (under 12 years of age) II APR / 07
LopinavirF1 I JUL / 03
LoprazolamTS I JUN / 02
Loracarbef and its salts and derivativesF1 I SEP / 98
Loratadine and its salts and preparations in products marketed for paediatric use - under 12 years of age III OCT / 02
Loratadine and its salts and preparations. in products marketed for adult use - 12 years and older U OCT / 02
Lorazepam and its saltsTS I SEP / 98
LormetazepamTS I JUN / 02
Losartan and its saltsF1 I SEP / 98
Losoxantrone and its saltsF1 I SEP / 98
LovastatinPDL

except in oral dosage form that provides 1 milligram (mg) or less per daily dose

I DEC / 14
Loxapine and its saltsF1 I SEP / 98
Lumacaftor or its salts or derivativesPDL I AUG / 16
LumiracoxibF1 I MAY / 09
Lutropin alfaF1 I OCT / 07
Lyme Disease vaccine I FEB / 02
Magnesium citrate cathartics III SEP / 98
Magnesium glutamate hydrobromideF1 I SEP / 98
Magnesium salicylate except oral dosage forms which also contain choline salicylate III SEP / 98
Magnesium sulfate for parenteral use II SEP / 98
Magnesium sulfate in injectable form for parenteral nutrition I JAN / 03
Manganese and its salts in injectable form for parenteral nutrition I JAN / 03
Mannitol and its salts II SEP / 98
Maprotiline and its saltsF1 I SEP / 98
MaravirocF1 I MAY / 09
Marbofloxacin and its salts and derivativesF1 I MAR / 01
Maropitant or its saltsPDL I DEC / 13
Mazindol and its saltsTS I SEP / 98
Measles vaccine II DEC / 98
MebendazoleF2 I SEP / 98
MebolazineC3 I JUN / 02
Mecamylamine and its saltsF1 I SEP / 98
Mechlorethamine and its saltsF1 I SEP / 98
Meclizine and its saltsF2

when sold in concentrations greater than 25 mg per dosage unit

I JUL / 00
Meclizine and its salts.

when sold in concentrations of 25 mg or less per dosage unit

III MAY / 00
Meclofenamic acid and its saltsF1 I SEP / 98
Mecloqualone and any salt thereofC5 I JAN / 03
MedazepamTS I JUN / 02
Medetomidine and its saltsF1 I MAY / 04
Mefenamic acid and its saltsF1 I SEP / 98
MefenorexTS I JUN / 02
Mefloquine and its salts and derivativesF1 I SEP / 98
Megestrol and its saltsF1 I SEP / 98
Melanoma therapeutic vaccineF1 I MAR / 01
Melarsomine and its saltsF1 when sold for the treatment of heartworm in dogs I MAY / 04
Meloxicam and its salts and derivativesF1 I OCT / 03
MelphalanF1 I SEP / 98
Memantine and its saltsF1 I SEP / 06
Meningococcus vaccine II MAR / 01
MenotropinsF1 human I SEP / 98
Mepacrine and its saltsF1 I SEP / 98
Mepazine and its saltsF1 I SEP / 98
MephenoxaloneF1 I SEP / 98
Mephentermine and its saltsF1 I SEP / 98
MephobarbitalC2 I JUN / 02
Mepivacaine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
Mepivacaine and its salts for ophthalmic or parenteral use II SEP / 98
MepolizumabPDL I AUG / 16
MeprobamateTS I SEP / 98
Mepyramine see pyrilamine U
MercaptopurineF1 I SEP / 98
Meropenem or its salts or derivativesPDL

including but not limited to doripenem

I DEC / 13
MesaboloneC3 I JUN / 02
MesnaF1 I SEP / 98
Mesocarb and any salt thereofC4 I JAN / 03
Mesoridazine and its saltsF1 I SEP / 98
MesteroloneC3 I JUN / 02
MetaldehydeF1 I SEP / 98
MetandienoneC3 I JUN / 02
Metaraminol bitartrate I SEP / 98
Metathoheptazine and its salts II SEP / 98
MetazocineN I JUN / 02
MetenoloneC3 I JUN / 02
Metformin and its salts and derivativesF1 I SEP / 98
MethabarbitalC2 I JUN / 02
Methacholine and its saltsF1 I SEP / 98
MethadoneN I JUN / 02
MethamphetamineC1 I JUN / 02
MethandriolC3 I JUN / 02
Methantheline and its salts II SEP / 98
MethaqualoneC1 I JUN / 02
Methazolamide and its saltsF1 I MAY / 00
Methdilazine and its salts II SEP / 98
Methenamine and its salts except for topical use II SEP / 98
Metheptazine and its salts II SEP / 98
MethimazoleF1 I SEP / 98
MethisazoneF1 I SEP / 98
Methocarbamol for parenteral use II SEP / 98
Methocarbamol. except for parenteral use III SEP / 98
MethoinF1 Mephenytoin and its salts I SEP / 98
Methotrexate and its saltsF1 I SEP / 98
Methotrimeprazine and its saltsF1 I SEP / 98
Methoxamine and its saltsF1 I SEP / 98
MethoxsalenF1 I SEP / 98
Methoxy polyethylene glycol-epoetin betaF1 I OCT / 09
Methyl salicylate in liquid dosage forms in concentrations greater than 30% II SEP / 98
Methyl salicylate. in liquid dosage forms in concentrations up to and including 30% U
MethyldesorphineN I JUN / 02
MethyldihydromorphineN I JUN / 02
Methyldopa and its saltsF1 I SEP / 98
Methylene Blue for parenteral use II SEP / 98
MethylparafynolF1 I SEP / 98
MethylphenidateC1 I JUN / 02
MethylphenobarbitalC2 I JUN / 02
MethylphenylisonipecotonitrileN I JUN / 02
MethyltestosteroneC3 I JUN / 02
MethyprylonTS I SEP / 98
Methysergide and its salts and derivativesF1 I SEP / 98
MetoclopramideF1 I SEP / 98
Metolazone and its saltsF1 I SEP / 98
Metomidate and its saltsF1 I SEP / 98
Metopimazine and its saltsF1 I SEP / 98
MetoponN I JUN / 02
Metoprolol and its saltsF1 I SEP / 98
MetriboloneC3 I JUN / 02
MetronidazoleF1 I SEP / 98
Metyrapone and its saltsF1 I SEP / 98
Mexiletine and its saltsF1 I SEP / 98
MiboleroneC3 I JUN / 02
Micafungin and its saltsF1 I JUN / 08
Miconazole and its saltsF1 except in preparations for topical or vaginal use I SEP / 98
Miconazole and its salts. for vaginal use III SEP / 98
Miconazole and its salts.. for topical use U
Midazolam and its saltsTS I SEP / 98
Midodrine and its saltsF1 I SEP / 98
Mifepristone or its derivativesPDL I AUG / 15
MiglustatF1 I APR / 07
Milbemycin and its derivativesF1 I SEP / 98
Milrinone and its saltsF1 I SEP / 98
Mineral tar except shampoos with concentrations less than 5% III SEP / 98
MinoxidilPDL

except when sold in preparations for topical use in concentrations of 5% or less, for human use only

I AUG / 14
Minoxidil.

when sold in preparations for topical use in adults in concentrations of 5% or less, for human use only

U JUL / 17
Mirtazapine and its saltsF1 I OCT / 03
Mitomycin and its saltsF1 I SEP / 98
MitotaneF1 I SEP / 98
Mitoxantrone and its saltsF1 I SEP / 98
MitratapidePDL I FEB / 14
Mivacurium chlorideF1 I SEP / 98
Moclobemide or its salts or derivativesPDL I DEC / 13
Modafinil and its saltsF1 I SEP / 06
MolgramostimF1 I SEP / 98
Mometasone furoateNR for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older I AUG / 15
Monobenzone II SEP / 98
Monoethanolamine oleate II SEP / 98
Montelukast and its saltsF1 I SEP / 99
MorpheridineN I JUN / 02
MorphineN I JUN / 02
Morphine-N-oxideN I JUN / 02
Moxidectin and its derivatives, when sold for the prevention of heartworm in dogsF1 I MAY / 04
Moxifloxacin and its salts and derivativesF1 I JUL / 03
Mumps vaccine II DEC / 98
Mupirocin I SEP / 99
Muromonab-CD3F1 I APR / 07
Mycophenolic acid and its salts and derivativesF1 I SEP / 98
MyrophineN I JUN / 02
NabumetoneF1 I SEP / 98
Nadolol and its saltsF1 I SEP / 98
Nadroparin and its saltsF1 I SEP / 99
Nafarelin and its salts and derivativesF1 I SEP / 98
Nalbuphine and any salt thereofC2 I JUN / 02
Nalidixic acidF1 I SEP / 98
Nalmefene and its saltsF1 I SEP / 99
NalorphineN I JUN / 02
Naloxegol or its saltsPDL

including but not limited to naloxegol oxalate

I JUN / 15
Naloxone hydrochloride injection,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone hydrochloride nasal spray,

when indicated for emergency use for opioid overdose

Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.

II FEB / 17
Naloxone or its saltsPDL

including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose

I FEB / 17
Naltrexone and its salts and derivativesF1 I OCT / 09
NandroloneC3 I JUN / 02
Naphazoline and its salts in nasal preparations for pediatric use II SEP / 98
Naphazoline and its salts. in nasal preparations for adult use and in ophthalmic products U
Naproxen or its saltsPDL

except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base)

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

I MAR / 15
Naproxen or its salts..

in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

U MAR / 15
Naproxen or its salts..

in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base

[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]

III MAR / 15
Naratriptan and its saltsF1 I SEP / 99
Narcotine and its salts Noscapine III SEP / 98
NatalizumabF1 I APR / 08
Nateglinide and its salts and derivativesF1 I OCT / 03
NecitumumabPDL I APR / 17
Nedocromil and its saltsF1 I SEP / 98
Nefazodone and its saltsF1 I SEP / 98
NelarabineF1 I MAY / 10
Nelfinavir and its saltsF1 I SEP / 99
Neocinchophen and its saltsF1 I SEP / 98
Neomycin and its salts and derivativesF2 I SEP / 98
Neostigmine saltsF1 I SEP / 98
NepafenacF1 I OCT / 09
Nesiritide or its saltsPDL I DEC / 13
Netilmicin and its salts and derivativesF1 I SEP / 98
Nevirapine and its saltsF1 I MAY / 00
Niacin in extended-release formulations nicotinic acid II DEC / 98
Niacin. in immediate-release formulations U DEC / 98
Niacinamide for topical use U OCT / 98
Niacinamide. oral U OCT / 98
Nialamide and its saltsF1 I SEP / 98
NicarbazinF2 I SEP / 98
Nicardipine and its saltsF1 I SEP / 98
NicocodineN I JUN / 02
NicomorphineN I JUN / 02
Nicotine and its salts, for human useF1

(except: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit. )

I JUN / 06
Nicotine and its salts.

when sold as a chewing gum containing not more than the equivalent of 4 mg of nicotine per dosage unit

U NOV / 00
Nicotine and its salts..

when sold as a transdermal patch with a delivery rate of not more than the equivalent of 22 mg

U NOV / 00
Nicotine and its salts...

when sold in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit

U JAN / 05
Nicotine and its salts....

when sold in the form of a lozenge containing 4 mg or less of nicotine per dosage unit

U JUN / 06
Nicotinic acidF1 When sold in (a) a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 mg per dosage unit or per daily dose I JUN / 08
Nicotinyl-tartrate I SEP / 98
NifedipineF1 I SEP / 98
Nikethamide I SEP / 98
Nilotinib and its saltsF1 I MAY / 10
NilutamideF1 I SEP / 98
NimetazepamTS I JUN / 02
Nimodipine and its saltsF1 I SEP / 98
Nintedanib or its saltsPDL I AUG / 15
NitisinonePDL I NOV / 16
Nitrazepam and its saltsTS I SEP / 98
Nitric oxideF1 I FEB / 07
Nitrofurantoin and its saltsF2 I SEP / 98
Nitroglycerin except for sublingual immediate release dosage forms I SEP / 98
Nitroglycerin. sublingual immediate release dosage forms II SEP / 98
NitroscanateF1 I MAY / 00
NivolumabPDL I JAN / 16
Nizatidine and its saltsF1 except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine I SEP / 98
Nizatidine and its salts when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine* I SEP / 98
Nomifensine and its saltsF1 I SEP / 98
NoracymethdolN I JUN / 02
NorboletoneC3 I JUN / 02
NorclostebolC3 I JUN / 02
NorcodeineN I JUN / 02
NordazepamTS I JUN / 02
Norepinephrine and its salts levarterenol, noradrenaline II SEP / 98
NorethandroloneC3 I JUN / 02
NorfloxacinF1 I SEP / 98
NorlevorphanolN I JUN / 02
NormethadoneN I JUN / 02
NormorphineN I JUN / 02
NorpethidineN I JUN / 02
NorpipanoneN I JUN / 02
Nortriptyline and its saltsF1 I SEP / 98
Noscapine III SEP / 98
Novobiocin and its salts and derivativesF2 I SEP / 98
NusinersenPDL I AUG / 17
Nylidrin and its saltsF1 I SEP / 98
Nystatin and its salts and derivativesF2 except preparations for topical use on the skin I SEP / 98
Nystatin and its salts and derivatives. in topical preparations for use on the skin III SEP / 98
Obeticholic acid or its saltsPDL I MAY / 17
ObinutuzumabPDL I DEC / 14
Oclacitinib or its saltsPDL

including but not limited to Oclacitinib maleate

I AUG / 14
Octatropine methylbromideF1 I SEP / 98
OctreotideF1 I SEP / 98
Ofloxacin and its saltsF1 I SEP / 98
Olanzapine and its saltsF1 I SEP / 99
OlaparibPDL I AUG / 16
Oleandomycin and its salts and derivativesF2 I SEP / 98
Olmesartan and its salts and derivativesF1 I MAR / 11
Olopatadine and its saltsF1 I SEP / 98
Olsalazine and its saltsF1 I SEP / 98
OmalizumabF1 I FEB / 07
OmbitasvirPDL I MAR / 15
Omeprazole or its saltsPDL

including but not limited to omeprazole, omeprazole magnesium except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of omeprazole

I SEP / 14
Omeprazole or its salts.

when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of omeprazole

II SEP / 14
Ondansetron and its saltsF1 I SEP / 98
OpiumN I JUN / 02
Orbifloxacin and its salts and derivativesF1 I MAY / 04
OrciprenalineF1 Metaproterenol and its salts I SEP / 98
Ormetoprim and its saltsF1 I SEP / 98
OrnidazoleF1 I SEP / 98
Orphenadrine citrate III SEP / 98
Orphenadrine hydrochloride I SEP / 98
Oseltamivir and its saltsF1 I MAR / 01
Osimertinib or its saltsPDL I AUG / 16
Oxabolone and its derivativesC3 I SEP / 98
OxaliplatinF1 I SEP / 08
OxanamideF1 I SEP / 98
OxandroloneC3 I JUN / 02
Oxaprozin and its salts and derivativesF1 I SEP / 98
Oxazepam and its saltsTS I SEP / 98
OxazolamTS I JUN / 02
OxcarbazepineF1 I DEC / 01
Oxethazine III SEP / 98
Oxiconazole 1% for topical use U SEP / 99
Oxolinic acid and its saltsF1 I SEP / 98
Oxprenolol and its saltsF1 I SEP / 98
Oxybuprocaine and its salts benoxinate for opthalmic or parenteral use II SEP / 98
Oxybuprocaine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
Oxybutynin and its saltsF1 I SEP / 98
OxycodoneN I JUN / 02
OxymesteroneC3 I JUN / 02
Oxymetazoline in nasal preparations for adult use and in ophthalmic products U
Oxymetazoline and its salts in nasal preparations for pediatric use II SEP / 98
OxymetholoneC3 I JUN / 02
OxymorphoneN I JUN / 02
Oxyphenbutazone and its saltsF1 I SEP / 98
Oxyquinoline II SEP / 98
OxytocinF1 I SEP / 98
Ozenoxacin or its saltsPDL I JUN / 17
Paclitaxel and its derivativesF1 I SEP / 98
Palbociclib or its saltsPDL I AUG / 16
PaliferminF1 I FEB / 07
Paliperidone and its salts and its derivativesF1 I MAY / 09
PalivizumabF1 I MAY / 04
Pamidronic acid and its saltsF1 I SEP / 98
Pancreatic extractsPDL

when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency

I DEC / 13
Pancreatic extracts, pancreatin, pancrelipase except when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency U DEC / 13
PancreatinPDL

when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency

I DEC / 13
PancrelipasePDL

when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency

I DEC / 13
Pancuronium and its saltsF1 I SEP / 98
PanitumumabF1 I OCT / 09
Pantoprazole and its saltsF1 I SEP / 98
Papain as a debriding agent U SEP / 99
Papaveretrine and its salts I SEP / 98
Papaverine and its salts I SEP / 98
ParaldehydeF1 I SEP / 98
ParamethadioneF1 I SEP / 98
Pargyline and its saltsF1 I SEP / 98
ParicalcitolF1 I FEB / 07
Paritaprevir (Veruprevir)PDL I MAR / 15
ParomomycinF1 I SEP / 98
Paroxetine and its saltsF1 I SEP / 98
Paroxypropione II SEP / 98
Pazopanib or its saltsPDL I DEC / 13
Pegaptanib and its saltsF1 I FEB / 07
PegaspargasePDL I APR / 17
PegfilgrastimF1 I APR / 07
PegvisomantF1 I FEB / 07
PembrolizumabPDL I JUN / 15
Pemetrexed and its saltsF1 I APR / 07
Pemoline and any salts thereofC4 I JAN / 03
Penciclovir and its saltsF1 I MAY / 00
PenicillamineF1 I SEP / 98
Penicillin or its salts or derivativesPDL

including but not limited to amoxicillin, ampicillin, azlocillin, benzathine penicillin, carbenicillin, cloxacillin, dicloxacillin, hetacillin, mecillinam, methicillin, mezlocillin, nafcillin, oxacillin and ticarcillin

I DEC / 13
Pentaerythritol tetranitrate I SEP / 98
Pentagastrin and its salts II SEP / 98
Pentamidine and its saltsF1 I SEP / 98
PentazocineN I JUN / 02
PentobarbitalC1 I JUN / 02
Pentolinium tartrateF1 I SEP / 98
Pentosan polysulfate and its saltsF1 I SEP / 98
Pentostatin and its saltsF1 I SEP / 98
Pentoxifylline and its saltsF1 I SEP / 98
Pepsin U
Peptone U
Peramivir or its salts or derivativesPDL I APR / 17
PerflutrenF1 I JUL / 03
Pergolide and its saltsF1 I SEP / 98
Pericyazine and its saltsF1 I SEP / 98
Perindopril and its saltsF1 I SEP / 98
Permethrin and its derivatives II SEP / 98
Perphenazine and its saltsF1 I SEP / 98
Pertussis vaccine II DEC / 98
PethidineN I JUN / 02
Pethidine Intermediate CN I JUN / 02
Phacetoperane and its saltsF1 I SEP / 98
PhenacemideF1 I SEP / 98
PhenacetinF1 I SEP / 98
PhenadoxoneN I JUN / 02
PhenaglycodolF1 I SEP / 98
PhenampromideN I JUN / 02
PhenazocineN I JUN / 02
Phenazopyridine and its saltsF1 I SEP / 98
PhencyclidineN I JUN / 02
Phendimetrazine and any salt thereofC1 I JUN / 02
Phenelzine and its saltsF1 I SEP / 98
Phenformin and its saltsF1 I SEP / 98
Pheniprazine and its saltsF1 I SEP / 98
Pheniramine U
Phenmetrazine and any salt thereofC1 I JUN / 02
PhenobarbitalC2 I JUN / 02
Phenol preparations with concentration of more than 20% II SEP / 98
PhenomorphanN I JUN / 02
PhenoperidineN I JUN / 02
Phenoxybenzamine and its salts II SEP / 98
Phentermine and any salt thereofC2 I JUN / 02
Phenthoxate and its saltsF1 I SEP / 98
Phentolamine or its saltsPDL I DEC / 13
Phenylbutazone and its saltsF1 I SEP / 98
Phenylbutyrate sodiumPDL I MAR / 15
Phenylephrine and its saltsF1 in preparations for parenteral use or ophthalmic use in concentrations greater than 2.5% I SEP / 98
Phenylephrine and its salts and preparations in nasal preparations in concentrations of 2.5% or less, for pediatric use II SEP / 98
Phenylephrine and its salts and preparations. for oral use, in nasal preparations for adults and in ophthalmic preparations in concentrations of 2.5% or less U
Phenylindanedione and its derivativesF1 I SEP / 98
Phenylmethylbarbituric AcidC2 I JUN / 02
Phenyltoloxamine and its salts III SEP / 98
PholcodineN I JUN / 02
Physostigmine salicylateF2 except preparations for oral or topical use only I SEP / 98
Physostigmine salicylate.

for oral or topical use

II SEP / 98
Pilocarpine and its saltsF1 I SEP / 98
PimecrolimusF1 I JUN / 06
PiminodineN I JUN / 02
PimobendanF1 I JUN / 08
PimozideF1 I SEP / 98
Pinaverium bromideF1 I SEP / 98
PinazepamTS I JUN / 02
Pindolol and its saltsF1 I SEP / 98
Pioglitazone and its salts.F1 I OCT / 03
Pipecuronium bromideF1 I SEP / 98
Piperacetazine and its saltsF1 I SEP / 98
Piperazine and its salts II SEP / 98
Piperilate and its saltsF1 I SEP / 98
PipobromanF1 I SEP / 98
Pipotiazine and its saltsF1 I SEP / 98
Pipradol and its saltsTS I SEP / 98
Pirbuterol and its saltsF1 I SEP / 98
Pirenzepine and its saltsF1 I SEP / 98
Pirlimycin and its saltsF1 I JUN / 08
Piroxicam and its saltsF1 I SEP / 98
Pizotyline and its saltsF1 I SEP / 98
Plerixafor or its saltsPDL I DEC / 13
Pneumococcal 7-valent conjugate vaccine II JAN / 04
Pneumococcal polysaccharide vaccines II FEB / 02
Podophyllum and the following extracts and active principlesF1 when sold or recommended for topical use: podophyllum toxin and podophyllum resin I SEP / 98
PolidocanolPDL

when indicated for administration by injection

I JAN / 16
Poliomyelitis vaccine II DEC / 98
Polyacrylamide II SEP / 98
Polyethylene glycol topical administration U
Polyethylene glycol 3350 as a single ingredient oral product indicated as a laxative to treat occasional constipation U JUL / 10
Polymyxin B or its salts or derivativesPDL

for human use, except for topical use or for local action in the oral cavity or nasal passages

I DEC / 13
Polymyxin B or its salts or derivatives.PDL

for veterinary use, when sold in combination with other medicinal ingredients

I APR / 16
Polymyxin B or its salts or derivatives..

for human, ophthalmic use

III JUN / 06
Polymyxin or its salts or derivatives for human, topical use U
Polysulfated glycosaminoglycanF1 I SEP / 98
Pomalidomide or its saltsPDL I FEB / 14
Ponatinib or its saltsPDL I MAY / 15
PonazurilF1 I SEP / 06
Poractant alfaF1 I MAR / 01
Porfimer and its saltsF1 I SEP / 98
PosaconazoleF1 I MAY / 09
Potassium bromidePDL I SEP / 98
Potassium citratePDL

when recommended for the treatment of renal tubular acidosis and kidney stones

I DEC / 13
Potassium gluconate when sold or recommended for administration to catsPDL I SEP / 98
Potassium para-aminobenzoatePDL

except in preparations for topical use on the skin

I SEP / 98
Potassium salts in preparations for injection I DEC / 99
Potassium salts. in oral preparations containing more than 5 mmol per single dose [except potassium bromide, potassium gluconate when sold or recommended for administration to cats, potassium para-aminobenzoate, potassium citrate when recommended for the treatment of renal tubular acidosis and kidney stones] II DEC / 13
Povidone - iodine vaginal preparations, except in concentrations of 5% or less II SEP / 98
Povidone - iodine topical preparations, except in concentrations of 5% or less III SEP / 98
Pradofloxacin or their salts or derivativesPDL I MAR / 15
Pralidoxime and its saltsF1 I SEP / 98
Pramipexole and its saltsF1 I SEP / 99
Pramoxine and its salts for ophthalmic or parenteral use II SEP / 98
Pramoxine and its salts.

for topical use on mucous membranes, except lozenges

III SEP / 98
Pramoxine and its salts.. for topical application on the skin, and including lozenges U DEC / 05
PrasteroneC3 I JUN / 02
Prasugrel or its saltsPDL I DEC / 13
Pravastatin and its saltsF1 I SEP / 98
Prazepam and its saltsTS I SEP / 98
Praziquantel, except when sold for the treatment of tapeworm Anoplocephala perfoliata in horsesF1 I MAY / 04
Prazosin and its saltsF1 I SEP / 98
Pregabalin and its salts and derivativesF1 I OCT / 07
Prenylamine and its saltsF1 I SEP / 98
Prilocaine and its salts

for ophthalmic or parenteral use

II SEP / 98
Prilocaine and its salts.

for topical use on mucous membranes, except lozenges

III SEP / 98
Primaquine and its saltsF1 I SEP / 98
PrimidoneF2 I SEP / 98
ProbarbitalC2 I JUN / 02
Probenecid and its saltsF1 I SEP / 98
ProbucolF1 I SEP / 98
Procainamide and its saltsF1 I SEP / 98
Procaine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
Procaine and its salts for ophthalmic or parenteral use II SEP / 98
Procarbazine and its saltsF1 I SEP / 98
Procaterol and its saltsF1 I SEP / 98
Prochlorperazine and its saltsF1 I SEP / 98
Procyclidine and its saltsF1 I SEP / 98
Prodilidine and its saltsF1 I SEP / 98
Profenamine and its saltsF1 I SEP / 98
Proguanil and its saltsF1 I SEP / 98
ProheptazineN I JUN / 02
Promazine and its saltsF2 I SEP / 98
Promethazine and its salts except for topical use II SEP / 98
Promethazine and its salts for topical use III SEP / 98
Propafenone and its saltsF1 I SEP / 98
PropallylonalC2 I JUN / 02
Propantheline and its salts II SEP / 98
Proparacaine and its salts for ophthalmic or parenteral use II SEP / 98
Proparacaine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
ProperidineN I JUN / 02
PropiramN I JUN / 02
Propiverine or its saltsPDL I APR / 17
PropofolF1 I SEP / 98
Propranolol and its saltsF1 I SEP / 98
Propylene glycol topical application U
Propylhexedrine II SEP / 98
Proquamezine [aminopromazine] and its salts for internal use I SEP / 98
Prostaglandins or their salts or derivatives or analoguesPDL

including but not limited to: Alprostadil, Bimatoprost, Cloprostenol, Dinoprostone, Epoprostenol, Fluprostenol, Latanoprost, Lubiprostone, Misoprostol, Tafluprost, Travoprost, Treprostinil, Unoprostone

I JAN / 16
Protamine and its salts II SEP / 98
Prothipendyl hydrochlorideF1 I SEP / 98
ProtirelinF1 I SEP / 98
Protriptyline and its saltsF1 I SEP / 98
Prucalopride or its saltsPDL

including but not limited to prucalopride succinate

I DEC / 13
Pseudoephedrine and its salts and preparations in combination products Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, pseudoephedrine products should not be located in a self-selection area of the pharmacy III APR / 06
Pseudoephedrine and its salts and preparations in single entity products II APR / 06
Pyrantel and its salts II SEP / 98
PyrazinamideF1 I SEP / 98
Pyrethrins II SEP / 98
Pyrethrins/piperonyl butoxide II SEP / 98
Pyridostigmine bromideF1 I SEP / 98
Pyrilamine U
Pyrimethamine and its saltsF1 I SEP / 98
Pyrovalerone and any salt thereofC4 I JAN / 03
Pyrvinium and its salts II SEP / 98
QuazepamTS I JUN / 02
Quetiapine and its saltsF1 I SEP / 99
Quinagolide and its saltsF1 I SEP / 98
Quinapril and its salts and derivativesF1 I SEP / 98
QuinboloneC3 I JUN / 02
Quinidine salts I SEP / 98
Quinine, its salts and derivativesF1 except when sold in oral dosage form that provides 50 mg or less of quinine base per dosage unit or per daily dose I NOV / 13
Quinupristin and its saltsF1 I DEC / 01
Rabeprazole and its saltsF1 I JUL / 03
Rabies immune globulin I FEB / 02
Rabies vaccine I FEB / 02
Racemethionine II SEP / 98
RacemethorphanN I JUN / 02
RacemoramideN I JUN / 02
RacemorphanN I JUN / 02
Raloxifene and its saltsF1 I SEP / 99
Raltegravir and its saltsF1 I MAY / 09
Raltitrexed and its salts and derivativesF1 I SEP / 98
Ramipril and its salts and derivativesF1 I SEP / 98
RamucirumabPDL I OCT / 15
RanibizumabF1 I SEP / 08
Ranitidine or its saltsPDL

except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn

I DEC / 13
Ranitidine or its salts. when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4,500 mg of ranitidine III MAR / 08
Ranitidine or its salts.. when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 4,500 mg of ranitidine U FEB / 07
Rasagiline and its saltsF1 I APR / 08
RasburicaseF1 I APR / 07
Raubasine and its saltsF1 I SEP / 98
RauwolfiaF1 I SEP / 98
RemifentanilN I JUN / 02
Remoxipride and its saltsF1 I SEP / 98
Repaglinide and its salts and derivativesF1 I MAY / 00
Rescinnamine and its saltsF1 I SEP / 98
Reserpine and its saltsF2 I SEP / 98
ReslizumabPDL I JUN / 17
Resocortol and its derivatives.FR AUG / 06
Resocortol and its derivatives..F1 I OCT / 07
RetapamulinF1 I OCT / 09
Reviparin and its saltsF1 I SEP / 98
Rho D immune globulin I FEB / 02
RibavirinF1 I SEP / 98
Rifabutin and its saltsF1 I SEP / 98
Rifampin and its salts and derivativesF1 I SEP / 98
Rilpivirine or its salts or derivativesPDL

including but not limited to rilpivirine hydrochloride

I DEC / 13
Riluzole and its saltsF1 I DEC / 02
Risedronic acid and its saltsF1 I MAR / 01
Risperidone and its saltsF1 I SEP / 98
Ritodrine and its saltsF1 I SEP / 98
RitonavirF1 I SEP / 98
RituximabF1 I DEC / 01
RivaroxabanF1 I MAY / 10
Rivastigmine and its saltsF1 I SEP / 99
Rocuronium bromideF1 I SEP / 98
RofecoxibF1 I MAR / 01
Roflumilast or its salts or derivativesPDL I DEC / 13
Romifidine and its saltsF1 I MAY / 04
RomiplostimF1 I MAR / 11
Ronidazole and its salts and derivativesF2 I SEP / 98
Ropinirole and its saltsF1 I SEP / 98
Rose Bengal II SEP / 98
Rosiglitazone and its saltsF1 I DEC / 01
Rosoxacin and its saltsF1 I SEP / 98
Rosuvastatin and its saltsF1 I JUN / 06
Rubella vaccine II DEC / 98
Rue and its preparations and extracts II SEP / 98
Rufinamide or its derivativesPDL I DEC / 13
RupatadinePDL I FEB / 17
Sacubitril or its saltsPDL I JAN / 16
Salbutamol and its saltsF1 I SEP / 98
Salicylic acidPDL

when sold in topical formulations containing salicylic acid at concentrations greater than 20% and/or with a pH less than 3.0, except when sold to be applied to warts, corns or calluses

I DEC / 14
Salicylic acid and its salts when sold to be applied to warts, corns or calluses in topical preparations in concentrations greater than 40% II DEC / 14
Salicylic acid and its salts.

in topical preparations in concentrations up to and including 40% (except when sold in topical formulations containing salicylic acid at concentrations greater than 20% and/or with a pH less than 3.0 for a use other than to be applied to warts, corns and calluses)

U DEC / 14
Salmeterol and its saltsF1 I SEP / 98
Salsalate and its salts and derivativesF1 I SEP / 98
Sapropterin or its saltsPDL I DEC / 13
Saquinavir and its salts and derivativesF1 I SEP / 98
Saralasin and its saltsF1 I SEP / 98
SargramostinF1 I SEP / 98
SarilumabPDL I APR / 17
SarolanerPDL

for veterinary use

I AUG / 16
Saxagliptin or its saltsPDL I DEC / 13
Scopolamine and its salts hyoscine, except Hyoscine butylbromide, when recommended for parenteral use II AUG / 16
SecobarbitalC1 I JUN / 02
SecukinumabPDL I MAY / 15
Selegiline and its saltsF1 I SEP / 98
Selenium in injectable form for parenteral nutrition I JAN / 03
Senna and its extracts and derivatives U
Sermorelin and its saltsF1 I SEP / 98
Sertraline and its saltsF1 I SEP / 98
Sevelamer and its saltsF1 I DEC / 01
SevofluranePDL I DEC / 13
Sex hormones (natural or synthetic)PDL

for human use, including but not limited to conjugated estrogens, desogestre, dienogest, estradiol benzoate, estradiol(hemihydrate), estrone, ethinyl estradiol, ethynodiol diacetate, etonogestrel, levonogestrel, medroxyprogesterone acetate, norelgestromin, norethindrone acetate, norgestimate, progesterone except as listed in the PDL

I AUG / 15
Sibutramine and its saltsF1 I SEP / 06
SigmodalC2 I JUN / 02
Sildenafil and its saltsF1 I MAY / 00
Silodosin or its salts or derivativesPDL I DEC / 13
SiltuximabPDL I DEC / 14
Silver nitrate II SEP / 98
SimvastatinF1 I SEP / 98
Sincalide II SEP / 98
Sirolimus and its derivativesF1 I JUL / 03
Sitagliptin and its saltsF1 I OCT / 09
Sitaxentan and its saltsF1 I JUN / 08
Sodium acetate for parenteral use II SEP / 98
Sodium acetate in injectable form for parenteral nutrition I JAN / 03
Sodium biphosphate

for parenteral use

II SEP / 98
Sodium biphosphate.

cathartics

III SEP / 98
Sodium bromideF1 I SEP / 98
Sodium chloride single ingredient solutions for parenteral or ophthalmic use in concentrations of more than 0.9% [NOTE: Does not apply to contact lens solutions intended to be rinsed off prior to insertion into eye] II OCT / 98
Sodium chloride in injectable form for parenteral nutrition I JAN / 03
Sodium citrate for parenteral use II SEP / 98
Sodium cromoglicate (cromoglycate) in solutions in concentrations of 2% or less for ophthalmic or nasal use III SEP / 98
Sodium fluoride (see Fluoride)F2 in solid oral dosage forms containing more than 1 mg of fluoride ion I SEP / 98
Sodium iodide for sclerosing II SEP / 98
Sodium iodine in injectable form for parenteral nutrition I JAN / 03
Sodium nitritePDL

when indicated for administration by injection and sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning

I JUN / 15
Sodium nitroprusside and its saltsF1 I SEP / 98
Sodium phosphate for parenteral use II SEP / 98
Sodium phosphate in injectable form for parenteral nutrition I JAN / 03
Sodium phosphate. cathartics III SEP / 98
Sodium picosulphate

for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5 g and citric acid 12 g)

II JAN / 10
Sodium polystyrene sulfonateF1 I SEP / 98
Sodium tartrate U
Sodium tetradecylsulfate II SEP / 98
Sofosbuvir or its saltsPDL I FEB / 14
Solifenacin and its saltsF1 I OCT / 07
SomatostatinF1 I SEP / 98
SomatremF1 I SEP / 98
SomatropinF1 I SEP / 98
Sorafenib and its saltsF1 I APR / 08
Sotalol and its saltsF1 I SEP / 98
Spectinomycin and its salts and derivativesF2 I SEP / 98
Spiramycin and its salts and derivativesF2 I SEP / 98
SpironolactoneF1 I SEP / 98
StanozololC3 I JUN / 02
StavudineF1 I SEP / 98
StenboloneC3 I JUN / 02
Stramonium, its preparations, extracts and compounds II SEP / 98
Streptokinase as a debriding agent II SEP / 98
Streptokinase/streptodornaseD I SEP / 98
Streptomycin and its salts and derivativesF2 I SEP / 98
StreptozocinF1 I SEP / 98
Strontium and its salts for parenteral use II SEP / 98
Strontium bromideF1 I SEP / 98
Succinimide and its salts and derivativesF1 except those compounds used for decontaminating water I SEP / 98
Succinylcholine and its saltsF1 I SEP / 98
SucralfateF1 I SEP / 98
SufentanilN I JUN / 02
Sulconazole and its saltsF1 I SEP / 98
Sulfinpyrazone and its saltsF1 I SEP / 98
Sulindac and its saltsF1 I SEP / 98
Sulphonamides and their salts and derivativesF2 I SEP / 98
Sulphones and their derivativesF1 I SEP / 98
Sumatriptan and its saltsF1 I SEP / 98
Sunitinib and its saltsF1 I OCT / 07
Suprofen and its saltsF1 I SEP / 98
Sutilains II SEP / 98
Suxamethonium chlorideF1 I SEP / 98
Synthetic cannabinoid receptor type-1 agonists, their salts, derivatives, isomers, and salts of derivatives and isomersN

with the exception of ((3S)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone (WIN 55,212-3) and its salts - as listed in the schedules to the Controlled Drugs and Substances Act and the Narcotic Control Regulations

I JUL / 15
Tacrolimus and its derivativesF1 I SEP / 98
TalbutalC2 I JUN / 02
Taliglucerase alfaPDL I JUL / 14
Tamoxifen and its saltsF1 I SEP / 98
Tamsulosin and its saltsF1 I SEP / 99
TapentadolN (3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-phenol), its salts, derivatives and isomers and salts of derivatives and isomers I JAN / 16
TazaroteneF1 I SEP / 98
Tazobactam and its salts and derivativesF1 I SEP / 98
Tedizolid or its salts or derivativesPDL

including but not limited to Tedizolid phosphate

I MAY / 15
TeduglutidePDL I OCT / 15
Tegafur and its saltsF1 I JUL / 03
Tegaserod and its saltsF1 I MAY / 04
Telaprevir or its derivativesPDL I DEC / 13
TelbivudineF1 I MAY / 09
Telithromycin and its salts and derivativesF1 I JUN / 06
Telmisartan and its salts and derivativesF1 I MAR / 01
Temazepam and its saltsTS I SEP / 98
Temozolomide and its saltsF1 I MAR / 01
TeniposideF1 I SEP / 98
Tenofovir and its salts and derivativesF1 I JUN / 06
Tenoxicam and its saltsF1 I SEP / 98
Terazosin and its saltsF1 I SEP / 98
Terbinafine and its saltsF1 I SEP / 98
Terbutaline and its saltsF1 I SEP / 98
Terconazole and its saltsF1 I SEP / 98
Terfenadine and its saltsF1 I SEP / 98
Teriparatide and its saltsF1 I APR / 07
Terlipressin and its saltsF1 I SEP / 98
Tesamorelin or its salts or derivativesPDL I MAY / 14
TestosteroneC3 I JUN / 02
Tetanus immune globulin I FEB / 02
Tetanus toxoid II DEC / 98
Tetrabenazine and its saltsF1 I SEP / 98
TetracainePDL

when in a preparation containing an equal amount of lidocaine and recommended for topical use on the skin, in concentrations of 7% or higher

I FEB / 14
Tetracaine and its salts

for ophthalmic or parenteral use

II SEP / 98
Tetracaine and its salts for topical use on mucous membranes, except lozenges III SEP / 98
Tetracycline and its salts and derivativesF2 except doxycycline when sold for intramuscular administration in caged birds I SEP / 98
Tetrahydrozoline in nasal preparations for pediatric use II SEP / 98
Tetrahydrozoline. for ophthalmic use and in nasal preparations for adults U
TetrazepamTS I JUN / 02
ThalidomideF1 I SEP / 98
ThebaconN I JUN / 02
Thebaine (paramorphine)N I JUN / 02
Theophylline and its saltsF1 I SEP / 98
ThiabendazoleF2 I SEP / 98
ThialbarbitalC2 I JUN / 02
ThiamylalC2 I JUN / 02
Thiethylperazine and its saltsF1 I SEP / 98
Thiobarbituric AcidC2 I JUN / 02
ThiocarlideF1 I SEP / 98
ThiofentanylN I JUN / 02
ThioguanineF1 I SEP / 98
ThiopentalC2 I JUN / 02
Thiopropazate and its saltsF1 I SEP / 98
Thioproperazine and its saltsF1 I SEP / 98
Thioridazine and its saltsF1 I SEP / 98
ThiotepaF1 I SEP / 98
Thiothixene and its saltsF1 I SEP / 98
Thiouracil and its derivativesF1 I SEP / 98
Thrombin II SEP / 98
Thyroglobulin II SEP / 98
ThyroidF2 I SEP / 98
Thyrotropin II SEP / 98
Thyrotropin alfaF1 I MAY / 04
Thyroxin and its saltsF1 I SEP / 98
Tiaprofenic acid and its saltsF1 I SEP / 98
TiboloneC3 I JUN / 02
Ticagrelor or its derivativesPDL I DEC / 13
Ticlopidine and its saltsF1 I SEP / 98
TigecyclineF1 I APR / 08
TildipirosinPDL

for veterinary use

I DEC / 14
Tilidine and its salts, derivatives and salts of derivativesN I JUN / 02
TilmicosinF1 I SEP / 98
Tiludronic acid and its saltsF1 I SEP / 98
Timolol and its saltsF1 I SEP / 98
TinidazoleF1 I SEP / 98
Tinzaparin and its saltsF1 I SEP / 98
Tioconazole and its saltsF1

except in preparations for topical or vaginal use in humans

I SEP / 98
Tioconazole and its salts.F2 I SEP / 98
Tioconazole and its salts.. in preparations for intra-vaginal use III OCT / 98
Tioconazole and its salts... in preparations for topical use U OCT / 98
TiomesteroneC3 I JUN / 02
Tiotropium bromideF1 I MAY / 04
Tipranavir and its saltsF1 I FEB / 07
Tirofiban and its salts and derivativesF1 I MAR / 01
Tizanidine and its saltsF1 I SEP / 99
Tobramycin and its salts and derivativesF1 I SEP / 98
Tocainide and its saltsF1 I SEP / 98
TocilizumabFR I APR / 10
Tofacitinib or its saltsPDL I MAY / 14
TolazamideF1 I SEP / 98
Tolazoline and its saltsF1 I SEP / 98
TolbutamideF1 I SEP / 98
TolcaponeF1 I SEP / 99
Tolfenamic acid and its salts and derivativesF1 I MAY / 04
Tolmetin and its saltsF1 I SEP / 98
Tolterodine and its saltsF1 I SEP / 99
Tolvaptan or its derivativesPDL I DEC / 13
TopiramateF1 I SEP / 98
Topotecan and its saltsF1 I SEP / 98
Torasemide and its saltsF1 I SEP / 98
Toremifine and its saltsF1 I SEP / 99
Trabectedin or its salts or derivativesPDL I DEC / 13
Tramadol or its saltsPDL I DEC / 13
Trandolaprilat and its salts and derivativesF1 I SEP / 98
Tranexamic acidF1 I SEP / 98
TranylcypromineF1 I SEP / 98
TrastuzumabF1 I MAR / 01
Trazodone and its saltsF1 I SEP / 98
TrenboloneC3 I JUN / 02
TreosulfanF1 I SEP / 98
TretamineF1 I SEP / 98
TretinoinF1 Vitamin A acid I SEP / 98
Tretinoin and its salts and derivativesF1 I SEP / 98
Triamcinolone acetonide

in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing more than 120 metered sprays

II JAN / 15
Triamcinolone acetonide.

in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing no more than 120 metered sprays

III JAN / 15
Triamterene and its saltsF1 I SEP / 98
Triazolam and its saltsTS I SEP / 98
Tricaine and its saltsF1 I SEP / 98
Triethanolamine oleate III SEP / 98
Triethanolamine salicylate in concentrations greater than 20% III SEP / 98
Triethanolamine salicylate. in concentrations up to and including 20% U
Trifluoperazine and its saltsF1 I SEP / 98
Triflupromazine and its saltsF1 I SEP / 98
TrifluridineF1 I SEP / 98
Trihexyphenidyl and its saltsF1 I SEP / 98
Triiodothyropropionic acidF1 I SEP / 98
TrilostaneF1 I SEP / 98
Trimebutine and its saltsF1 I SEP / 98
TrimeperidineN I JUN / 02
Trimeprazine and its saltsF2 I SEP / 98
TrimethadioneF1 I SEP / 98
Trimethaphan camsylateF1 I SEP / 98
Trimethoprim and its saltsF1 I SEP / 98
Trimetrexate and its saltsF1 I SEP / 98
Trimipramine and its saltsF1 I SEP / 98
TrioxsalenF1 I SEP / 98
Tripelennamine and its salts III SEP / 98
Triprolidine III SEP / 98
TroglitazoneF1 I SEP / 98
Tropicamide and its saltsF1 in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada I SEP / 98
Trospium chlorideF1 I OCT / 07
Trovafloxacin or its salts or derivativesPDL

including but not limited to alatrofloxacin

I DEC / 13
Trypsin U DEC / 98
Tryptophan (L-Tryptophan)F1

when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other indredients; or b) for human or veterinary use as a single ingredient inteded for any route of administration other than oral

I DEC / 11
Tubocurarine and its salts I SEP / 98
Tubocurarine chlorideF1 I SEP / 98
TybamateF1 I SEP / 98
Tylosin or its saltsPDL

for veterinary use, when sold for the treatment of chronic colitis in dogs

I DEC / 14
Tylosin or its salts or derivativesPDL

for human use, including but not limited to tildipirosin, tilmicosin

I DEC / 14
Typhoid vaccines/Salmonella Typhi vaccines I FEB / 02
Tyrothricine III SEP / 98
Ubiquinone U DEC / 98
Umeclidinium or its salts or derivativesPDL I FEB / 14
Uracil and its saltsF1 when sold for the treatment of cancer I DEC / 11
Urea in topical preparations in concentrations of more than 25% II SEP / 98
UrokinasePDL I DEC / 13
Ursodeoxycholic acid and its saltsF1 I SEP / 98
UstekinumabF1 I MAR / 11
Vaccines (except for - those which are part of a routine immunization program in most/all provinces and territories: Diphtheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus) I FEB / 02
Vaccines. which are part of a routine immunization program in most/all provinces and territories: Diptheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus II FEB / 02
Valaciclovir and its saltsF1 I SEP / 98
Valdecoxib and its saltsF1 I MAY / 04
Valganciclovir and its salts and derivativesF1 I MAY / 04
Valproic acid and its saltsF1 I SEP / 98
Valrubicin and its derivativesF1 I DEC / 02
Valsartan and its salts and derivativesF1 I SEP / 99
Vancomycin and its salts and derivativesF1 I SEP / 98
Vardenafil and its saltsF1 I APR / 07
Varenicline or its saltsPDL I DEC / 13
Varicella Zoster immune globulin I FEB / 02
Varicella vaccine (chicken pox) I FEB / 02
Vasopressin and its saltsF1 I SEP / 98
Vecuronium bromideF1 I SEP / 98
Vedaprofen and its salts and derivativesF1 I MAY / 00
VedolizumabPDL I MAR / 15
Vegetable tar except shampoos in concentrations of 5% or less III SEP / 98
Velaglucerase alfaPDL I DEC / 13
VelpatasvirPDL I AUG / 16
Venetoclax or its saltsPDL I NOV / 16
Venlafaxine and its saltsF1 I SEP / 98
Verapamil and its saltsF1 I SEP / 98
Veratrum album and its alkaloids and their saltsF2 I SEP / 98
Veratrum viride and its alkaloids and their saltsF2 I SEP / 98
Vernakalant or its saltsPDL I APR / 17
VidarabineF1 I SEP / 98
Vigabatrin and its salts and derivativesF1 I SEP / 98
Vilazodone or its saltsPDL I AUG / 15
VinbarbitalC2 I JUN / 02
Vinblastine and its saltsF1 I SEP / 98
Vincristine and its saltsF1 I SEP / 98
Vindesine and its saltsF1 I SEP / 98
Vinorelbine and its saltsF1 I SEP / 98
VinylbitalC2 I JUN / 02
Viomycin and its salts and derivativesF1 I SEP / 98
Virginiamycin and its salts and derivativesF2 I SEP / 98
Vitamin APDL

in oral dosage forms containing more than 10,000 International Units of Vitamin A per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 International Units of Vitamin A

I DEC / 13
Vitamin B12 with Intrinsic Factor ConcentrateF1 I SEP / 98
Vitamin DPDL

in oral dosage form containing more than 1,000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by the person of more than 1,000 International Units of Vitamin D

I DEC / 13
Vitamin KF2 except Vitamin K1 and Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less I OCT / 05
Vitamins any parenterals not otherwise included in Schedule I II SEP / 98
Vitamins in injectable form for parenteral nutrition I JAN / 03
Vorapaxar or its saltsPDL I AUG / 16
VoriconazoleF1 I FEB / 07
VorinostatF1 I MAR / 11
Vortioxetine or its saltsPDL

including but not limited to vortioxetine hydrobromide

I DEC / 14
Xanthinol nicotinateF1 I SEP / 98
Xylazine and its saltsF1 I SEP / 98
Xylometazoline and it salts in nasal preparations for pediatric use (0.05%) II SEP / 98
Xylometazoline and its salts in nasal preparations for adults (0.1%) U
Xylose II SEP / 98
Yellow Fever vaccine I FEB / 02
Yohimbine and its saltsF1 I SEP / 98
Zafirlukast and its saltsF1 I SEP / 99
Zalcitabine and its saltsF1 I SEP / 98
Zanamivir and its salts and derivativesF1 I DEC / 01
ZeranolC3 I SEP / 98
ZidovudineF1 I SEP / 98
Zinc chloride in injectable form for parenteral nutrition I JAN / 03
Zinc sulfate in injectable form for parenteral nutrition I JAN / 03
Ziprasidone and its saltsF1 I MAY / 09
Zoledronic acid and its salts and derivativesF1 I DEC / 02
Zolpidem and any salts thereofTS I JAN / 03
Zomepirac and its saltsF1 I SEP / 98
Zopiclone and its saltsF1 I SEP / 98
ZucapsaicinPDL I DEC / 13
Zuclopenthixol and its salts and derivativesF1 I SEP / 98
a - MethylthiofentanylN I JUN / 02
alpha1- proteinase inhibitor (human) I JAN / 06
p-FluorofentanylN I JUN / 02

1876 result(s)

Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled